0001493152-16-009773.txt : 20160513 0001493152-16-009773.hdr.sgml : 20160513 20160513170236 ACCESSION NUMBER: 0001493152-16-009773 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160513 DATE AS OF CHANGE: 20160513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDICA Corp CENTRAL INDEX KEY: 0001269026 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33624 FILM NUMBER: 161649336 BUSINESS ADDRESS: STREET 1: 1885 WEST 2100 STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84119 BUSINESS PHONE: 801-839-3516 MAIL ADDRESS: STREET 1: 1885 WEST 2100 STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84119 FORMER COMPANY: FORMER CONFORMED NAME: AMEDICA CORP DATE OF NAME CHANGE: 20031104 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

[ ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-33624

Amedica Corporation

(Exact name of registrant as specified in its charter)

DELAWARE		84-1375299
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

1885 West 2100 South, Salt Lake City, UT		84119
(Address of principal executive offices)		(Zip Code)

(801) 839-3500

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days: Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files); Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	[ ]	Accelerated filer	[ ]

Non-accelerated filer	[ ] (Do not check if a smaller reporting company)	Smaller reporting company	[X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): [ ] Yes [X] No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

13,236,071 shares of common stock, $0.01 par value, were outstanding at May 13, 2016

Amedica Corporation

Table of Contents

Part I. Financial Information

Item 1. Financial Statements

Condensed Consolidated Balance Sheet (unaudited)	3

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)	4

Condensed Consolidated Statement of Cash Flows (unaudited)	5

Notes to Condensed Consolidated Financial Statements (unaudited)	6

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

Item 3. Quantitative and Qualitative Disclosures About Market Risk	19

Item 4. Controls and Procedures	19

Part II. Other Information

Item 1. Legal Proceedings	20

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	20

Item 3. Defaults Upon Senior Securities	20

Item 4. Mine Safety Disclosures	20

Item 5. Other Information	20

Item 6. Exhibits	21

Signatures	22

Amedica Corporation

Condensed Consolidated Balance Sheets - Unaudited

(in thousands, except share and per share data)

	March 31, 2016		December 31, 2015
Assets
Current assets:
Cash and cash equivalents	$	7,943	$	11,485
Trade accounts receivable, net of allowance of $28 and $49, respectively		1,848		2,660
Prepaid expenses and other current assets		705		229
Inventories, net		8,492		9,131
Total current assets		18,988		23,505

Property and equipment, net		2,333		2,472
Intangible assets, net		3,562		3,687
Goodwill		6,163		6,163
Other long-term assets		35		35
Total assets	$	31,081	$	35,862

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	982	$	643
Accrued liabilities		3,203		3,421
Current portion of long-term debt		14,785		16,365
Total current liabilities		18,970		20,429

Deferred rent		405		432
Other long-term liabilities		169		171
Derivative liabilities		604		598

Commitments and contingencies
Stockholders’ equity:
Common stock, $0.01 par value; 250,000,000 shares authorized; 11,422,636 and 10,886,248 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively		114		109
Additional paid-in capital		210,744		210,660
Accumulated deficit		(199,925)		(196,537)
Total stockholders’ equity		10,933		14,232
Total liabilities and stockholders’ equity	$	31,081	$	35,862

See accompanying notes.

Amedica Corporation

Condensed Consolidated Statements of Operations and Comprehensive Loss - Unaudited

(in thousands, except share and per share data)

	Three Months Ended March 31,
	2016		2015
Product revenue	$	4,173	$	4,743
Costs of revenue		893		1,522
Gross profit		3,280		3,221
Operating expenses:
Research and development		1,608		1,843
General and administrative		1,562		2,027
Sales and marketing		2,594		3,357
Total operating expenses		5,764		7,227
Loss from operations		(2,484)		(4,006)
Other income (expense):
Interest expense		(900)		(1,100)
Loss on extinguishment of debt		-		(79)
Change in fair value of derivative liabilities		(11)		(177)
Loss on extinguishment of derivative liabilities		-		(16)
Other expense		7		(3)
Total other income (expense)		(904)		(1,375)
Net loss before income taxes		(3,388)		(5,381)
Provision for income taxes		-		-
Total comprehensive loss	$	(3,388)	$	(5,381)
Net loss per share attributable to common stockholders:
Basic and diluted	$	(0.30)	$	(3.00)
Weighted average common shares outstanding:
Basic and diluted		11,193,250		1,795,296

See accompanying notes.

Amedica Corporation

Condensed Consolidated Statements of Cash Flows - Unaudited

(in thousands)

	Three Months Ended March 31,
	2016		2015
Cash flow from operating activities
Net loss	$	(3,388)	$	(5,381)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		389		428
Amortization of intangible assets		125		125
Amortization of lease incentive for tenant improvements		5		5
Non cash interest expense		405		551
Loss on extinguishment of debt		-		79
Stock based compensation		88		592
Change in fair value of derivative liabilities		6		177
Loss on extinguishment of derivative liabilities		-		16
(Gain) loss on disposal of equipment		(4)		3
Provision for inventory reserve		373		326
Bad debt recovery		-		(20)
Changes in operating assets and liabilities:
Trade accounts receivable		813		(35)
Prepaid expenses and other current assets		(476)		(330)
Inventories		263		293
Accounts payable and accrued liabilities		(64)		200
Net cash used in operating activities	$	(1,465)	$	(2,971)
Cash flows from investing activities
Purchase of property and equipment		(259)		(277)
Proceeds from sale of property and equipment		16		3
Net cash used in investing activities	$	(243)	$	(274)
Cash flows from financing activities
Payments on long-term debt		(1,834)		-
Purchase of treasury stock		-		(120)
Net cash used in financing activities	$	(1,834)	$	(120)
Net decrease in cash and cash equivalents		(3,542)		(3,365)
Cash and cash equivalents at beginning of period		11,485		18,247
Cash and cash equivalents at end of period	$	7,943	$	14,882

Noncash investing and financing activities
Debt converted to common stock	$	-	$	202
Common stock issued for cashless exercise of warrant derivative liabilities	$	-	$	739
Supplemental cash flow information
Cash paid for interest	$	507	$	548

See accompanying notes.

AMEDICA CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Organization and Summary of Significant Accounting Policies

Organization

Amedica Corporation (“Amedica” or “the Company”) was incorporated in the state of Delaware on December 10, 1996. Amedica is a commercial-stage biomaterials company focused on using its silicon nitride technology platform to develop, manufacture, and commercialize a broad range of medical devices. The Company believes it is the first and only manufacturer to use silicon nitride in medical applications. The Company acquired US Spine, Inc. (“US Spine”), a Delaware spinal products corporation with operations in Florida, on September 20, 2010. The Company’s products are sold primarily in the United States.

Basis of Presentation

These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”). Such rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 23, 2016. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2015.

In accordance with the adoption of Accounting Standards Update (“ASU”) 2015-03, the Company’s debt issuance costs have been reclassified to be presented in the Condensed Consolidated Balance Sheets as a direct reduction from the debt liability rather than as an asset.

The following is a reconciliation of the effect of these reclassifications on the Company’s Condensed Consolidated Balance Sheet at December 31, 2015 (in thousands):

	December 31, 2015
	As Reported		Adjustments		As Revised
Assets:
Prepaid expenses and other current assets	$	821	$	(592)	$	229
Liabilities:
Current portion of long-term debt		16,957		(592)		16,365

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Some of the more significant estimates relate to inventory, stock-based compensation, long-lived and intangible assets and the liability for preferred stock and common stock warrants.

Liquidity and Capital Resources

For the three months ended March 31, 2016 and 2015, the Company incurred a net loss of $3.4 million and $5.4 million, respectively, and used cash in operations of $1.5 million and $3 million, respectively. The Company had an accumulated deficit of $199.9 million and $196.5 million at March 31, 2016 and December 31, 2015, respectively. To date, the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock, convertible debt and bank debt and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations through 2016.

As discussed further in Note 7, the Company has entered into a term loan with Hercules Technology Growth Capital, Inc. (“Hercules Technology”), as administrative and collateral agent for the lenders thereunder and as lender, and Hercules Technology III, LP, (“HT III” and, together with Hercules Technology, “Hercules”) as lender (the “Hercules Term Loan”). The Hercules Term Loan has a liquidity covenant that requires the Company to maintain a cash balance of not less than $7.0 million at March 31, 2016. At March 31, 2016, the Company’s cash balance was approximately $7.9 million. The Company anticipates that it will need to refinance the note or obtain additional funding early in the third quarter of 2016 to maintain compliance through 2016 with the liquidity covenant related to the Hercules Term Loan. However, if the Company is unable to refinance the note or access additional funds prior to becoming non-compliant with the financial and liquidity covenants related to the Hercules Term Loan, the entire remaining balance of the debt under the Hercules Term Loan could become immediately due and payable at the option of the lender. Although the Company is seeking to refinance the note or obtain additional financing, additional funding may not be available to the Company on favorable or acceptable terms, or at all. Any additional equity financing, if available to the Company, will most likely be dilutive to its current stockholders, and debt financing, if available, may involve more restrictive covenants. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, will materially harm its business, financial condition and results of operations. These uncertainties create substantial doubt about the Company’s ability to continue as a going concern. No adjustment has been made to our financial statements as a result of this uncertainty.

See Note 11. Subsequent Events for further discussion with respect to the assignment of $3.0 million of the principal balance of the Hercules Term Loan to Riverside Merchant Partners, LLC (“Riverside”) and the subsequent agreement between the Company and Riverside to exchange the $3.0 million of the Hercules Term Loan held by Riverside for subordinated convertible promissory notes in the aggregate principal amount of $3.0 million.

Significant Accounting Policies

There have been no significant changes to the Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

New Accounting Pronouncements

In March 2016 the Financial Accounting Standards Board (“FASB”) updated the accounting guidance related to stock compensation. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company is still evaluating the impact that this standard will have on its consolidated financial statements.

In February 2016, the FASB updated the accounting guidance related to leases as part of a joint project with the International Accounting Standards Board (“IASB”) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, a lessee will be required to recognize assets and liabilities for capital and operating leases with lease terms of more than 12 months. Additionally, this ASU will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases, including qualitative and quantitative requirements. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the potential impact this new standard may have on its financial statements.

In August 2014, the FASB updated the accounting guidance related to disclosure of uncertainties about an entity’s ability to continue as a going concern. The new standard provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. It requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern. The new standard is effective for annual periods ending after December 15, 2016, and interim periods thereafter. Early adoption is permitted. The impact on the Company’s financial statements of adopting the new standard is currently being assessed by management.

In May 2014, the FASB updated the accounting guidance related to revenue from contracts with customers, which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle is that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The standard defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, and shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is evaluating the potential impact of this adoption on its consolidated financial statements.

2. Basic and Diluted Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of warrants for the purchase of common stock, convertible notes, stock options and unvested restricted stock units. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding because their effect would have been anti-dilutive due to the Company reporting a net loss. The Company had potentially dilutive securities representing approximately 800,000 and 2.9 million shares of common stock at March 31, 2016 and 2015, respectively.

3. Inventories

The components of inventory were as follows (in thousands):

	March 31, 2016		December 31, 2015
Raw materials	$	788	$	819
WIP		229		235
Finished Goods		7,475		8,077
Total inventory	$	8,492	$	9,131

Finished goods include consigned inventory in the amounts of approximately $3.4 million and $3.8 million as of March 31, 2016 and December 31, 2015, respectively.

4. Intangible Assets

Intangible assets consisted of the following (in thousands):

	March 31, 2016		December 31, 2015
Customer relationships	$	3,990	$	3,990
Developed technology		4,685		4,685
Other patents and patent applications		562		562
Trademarks		350		350
Total intangibles		9,587		9,587
Less accumulated amortization		(6,025)		(5,900)
Total intangibles net of amortization	$	3,562	$	3,687

Based on the recorded intangibles at March 31, 2016, the estimated amortization expense is expected to be $375,000 during the remainder of 2016 and approximately $501,000 per year through 2020 and $834,000 thereafter.

5. Fair Value Measurements

Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis

The Company measures and records certain financial instruments at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:

Level 1	-	quoted market prices for identical assets or liabilities in active markets.

Level 2	-	observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

Level 3	-	unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

The Company classifies assets and liabilities measured at fair value in their entirety based on the lowest level of input that is significant to their fair value measurement. No financial assets were measured on a recurring basis at March 31, 2016 and December 31, 2015. The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy at March 31, 2016 and December 31, 2015:

	Fair Value Measurements at March 31, 2016
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	604	$	604

	Fair Value Measurements at December 31, 2015
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	598	$	598

The Company did not have any transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy during the three months ended March 31, 2016 and 2015. The following table presents a reconciliation of the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2016 and 2015:

	Common Stock Warrants		Preferred Stock Warrants		Conversion Feature of Notes		Total Derivative Liability
Balance at December 31, 2014	$	(11,358)	$	-	$	(2,612)	$	(13,970)
Decrease in liability due to debt conversions		-		-		179		179
Decrease in liability due to warrants being exercised		723		-		-		723
Change in fair value		435		-		(612)		(177)
Balance at March 31, 2015	$	(10,200)	$	-	$	(3,045)	$	(13,245)

Balance at December 31, 2015	$	(598)	$	-	$	-	$	(598)
Increase in fair value included in earnings, as other income		(6)		-		-		(6)
Balance at March 31, 2016	$	(604)	$	-	$	-	$	(604)

Common Stock Warrants

The Company has issued certain warrants to purchase shares of common stock, which are considered mark-to-market liabilities and are re-measured to fair value at each reporting period in accordance with accounting guidance.

The assumptions used in estimating the common stock warrant liability at March 31, 2016 and December 31, 2015 were as follows:

	March 31,2016		December 31, 2015
Weighted-average risk free interest rate		1.06%		1.71%
Weighted-average expected life (in years)		3.55		3.7
Expected dividend yield		0%		0%
Weighted average expected volatility		137%		119%

Other Financial Instruments

The Company’s recorded values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The recorded value of notes payable approximates the fair value as the interest rate approximates market interest rates.

6. Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	March 31, 2016		December 31, 2015
Commissions	$	563	$	867
Payroll and related expenses		359		683
Royalties		478		515
Interest payable		237		222
Final loan payment fees		922		783
Other		644		351
Total accrued liabilities	$	3,203	$	3,421

7. Debt

Hercules Term Loan

On June 30, 2014, the Company entered into a Loan and Security Agreement with Hercules which provided the Company with a $20 million term loan. The Hercules Term Loan matures on January 1, 2018. The Hercules Term Loan included a $200,000 closing fee, which was paid to Hercules on the closing date of the loan. The closing fee was recorded as a debt discount and is being amortized to interest expense over the life of the loan. The Hercules Term Loan also includes a non-refundable final payment fee of $1.7 million. The final payment fee is being accrued and recorded to interest expense over the life of the loan. The Hercules Term Loan bears interest at the rate of the greater of either (i) the prime rate plus 9.2%, and (ii) 12.5%, and was 12.7% at March 31, 2016. Interest accrues from the closing date of the loan and interest payments are due monthly. Principal payments commenced August 1, 2015 and are to be made in 30 equal installments of approximately $700,000, with the remainder due at maturity. The Company’s obligations to Hercules are secured by a first priority security interest in substantially all of its assets, including intellectual property. The Hercules Term Loan contains certain covenants related to restrictions on payments to certain Company affiliates and financial reporting requirements.

On September 8, 2015, the Company entered into a Consent and First Amendment to Loan and Security Agreement (the “Amendment”) with Hercules. The Amendment modified the liquidity covenant to reduce the minimum cash balance required by $500,000 for every $1.0 million paid in principal to a minimum of $2.5 million. The minimum cash and cash equivalents balance required to maintain compliance with the minimum liquidity covenant at March 31, 2016 was $7.0 million. Although the Company was in compliance with the liquidity covenant at March 31, 2016, the Company anticipates that it will be non-compliant with the liquidity covenant early in the third quarter of 2016 if additional financing is not obtained or the loan is not restructured, and has therefore classified the entire obligation as a current liability.

Magna Note

In August 2014, the Company entered into a Securities Purchase Agreement with Magna pursuant to which the Company sold to Magna an unsecured promissory note with an aggregate principal amount of $3.5 million (the “Magna Note”). The outstanding principal amount of the Magna Note was $763,000 at March 31, 2016. The Magna Note matures on August 11, 2016, and accrues interest at an annual rate of 6.0%.

Outstanding long-term debt consisted of the following (in thousands):

	March 31, 2016						December 31, 2015
	Outstanding Principal		Unamortized Discount and Debt Issuance Costs		Net Carrying Amount		Outstanding Principal		Unamortized Discount and Debt Issuance Costs		Net Carrying Amount
Hercules Term Loan		15,218		(1,186)		14,032		17,051		(1,420)		15,631
Magna Note		763		(10)		753		763		(29)		734
Total debt		15,981		(1,196)		14,785		17,814		(1,449)		16,365
Less: Current portion		(15,981)		1,196		(14,785)		(17,814)		1,449		(16,365)
Long-term debt	$	-	$	-	$	-	$	-	$	-	$	-

The following summarizes by year the future principal payments as of March 31, 2016 (in thousands):

Years Ending December 31,	Hercules Term Loan		Magna Note		Total
2016	$	5,787	$	763	$	6,550
2017		8,643		-		8,643
2018		788		-		788
Total future principal payments	$	15,218	$	763	$	15,981

8. Equity

536,388 shares of common stock were issued upon the cashless exercise of 1,137,365 Series A warrants issued in September 2015. The remaining number of Series A warrants was 100,000 at March 31, 2016.

9. Stock-Based Compensation

Option and Equity Plans

In January 2016, the aggregate number of shares issuable under the 2012 Employee, Director and Consultant Equity Incentive Plan (the “2012 Plan”) was increased by 37,879 to 342,425, in accordance with the 2012 plan.

The total number of shares available for grant under the 2012 Plan at March 31, 2016 was 121,248.

Stock Options

A summary of the Company’s stock option activity for the three months ended March 31, 2016 was as follows:

	Options		Weighted-Average Exercise Price
Outstanding at December 31, 2015		112,373	$	41.53
Granted		23,004	$	1.69
Expired		13,702	$	24.17
Outstanding at March 31, 2016		121,675	$	35.95
Exercisable at March 31, 2016		74,859	$	60.65
Vested and expected to vest at March 31, 2016		119,112	$	36.50

The Company estimates the fair value of each stock option on the grant date using the Black-Scholes-Merton valuation model, which requires several estimates including an estimate of the fair value of the underlying common stock on grant date. The expected volatility was based on an average of the historical volatility of a peer group of similar companies. The expected term was calculated utilizing the simplified method. The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the option. The following weighted average assumptions were used in the calculation to estimate the fair value of options granted to employees during the three months ended March 31, 2016 and 2015:

	Three Months Ended March 31,
	2016		2015
Weighted-average risk-free interest rate		1.86%		1.62%
Weighted-average expected life (in years)		6.3		6.3
Expected dividend yield		0%		0%
Weighted-average expected volatility		65%		46%

Summary of Stock-Based Compensation Expense

Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss was allocated as follows (in thousands):

	Three Months Ended March 31,
	2016		2015
Cost of revenue	$	4	$	29
Research and development		29		122
General and administrative		40		328
Selling and marketing		15		142
Capitalized into inventory		2		39
Total stock-based compensation expense	$	90	$	660

Unrecognized stock-based compensation at March 31, 2016 was as follows (in thousands):

		Unrecognized Stock-Based Compensation				Weighted Average Remaining Period of Recognition (in years)
Stock options		$	435				1.7

10. Commitments and Contingencies

On April 1, 2016, Hampshire MedTech Partners II, GP (“Hampshire GP”) filed suit against the Company in the Travis County, Texas 200th Judicial District Court relating to a Warrant to Purchase Shares of Common Stock issued to Hampshire MedTech Partners II, LP (“Hampshire LP”) on November 6, 2014 (the “Warrant”). Hampshire GP alleges that as a result of a subsequent financing the Company breached the anti-dilution provision of the Warrant by failing to increase the number of shares subject to the Warrant as well as failing to reduce the exercise price of the Warrant. Hampshire GP seeks damages in excess of $1,000,000. The Company has not yet answered Hampshire GP’s complaint and intends to vigorously defend itself in this suit.

From time to time, the Company is subject to other various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. Management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results or cash flows.

11. Subsequent Events

Hercules and Riverside Debt Assignment

On April 4, 2016, the Company entered into an Assignment and Second Amendment to Loan and Security Agreement (the “Assignment Agreement”) with Riverside Merchant Partners, LLC (“Riverside”), and Hercules, pursuant to which Hercules sold $1.0 million of the principal amount outstanding under the Hercules Term Loan, as amended to Riverside. In addition, pursuant to the terms of the Assignment Agreement, Riverside acquired an option to purchase an additional $2.0 million of the principal amount outstanding under the Hercules Term Loan from Hercules. On April 18, 2016, Riverside purchased an additional $1.0 million of the principal amount of the Hercules Term Loan and on April 27, 2016, Riverside purchased an additional $1.0 million of the principal amount of the Hercules Term Loan from Hercules.

Riverside Debt Exchange

On April 4, 2016, the Company entered into an exchange agreement (the “Exchange Agreement”) with Riverside, pursuant to which the Company agreed to exchange $1.0 million of the principal amount outstanding under the Hercules Term Loan held by Riverside for a subordinated convertible promissory note in the principal amount of $1.0 million (the “First Exchange Note”) and a warrant to purchase 100,000 shares of common stock of the Company at a fixed exercise price of $1.62 per share (the “First Exchange Warrant”) (the “Exchange”). In addition, pursuant to the terms and conditions of the Exchange Agreement, the Company and Riverside had the option to exchange an additional $2.0 million of the principal amount of the Hercules Term Loan for an additional subordinated convertible promissory note in the principal amount of up to $2.0 million and an additional warrant to purchase 100,000 shares of common stock (the “Second Exchange Warrant”). On April 18, 2016, the Company and Riverside exercised their option to exchange an additional $1.0 million of the principal amount of the Hercules Term Loan for an additional subordinated convertible promissory note in the principal amount of $1.0 million (the “Second Exchange Note”). Additionally, on April 27, 2016, the Company and Riverside exercised their option to exchange an additional $1.0 million of the principal amount of the Term Loan for an additional subordinated convertible promissory note in the principal amount of $1.0 million (the “Third Exchange Note”) and an additional warrant to purchase 100,000 shares of the Company’s common stock at a fixed exercise price of $1.66 per share. The First Exchange Note, the Second Exchange Note and the Third Exchange Note are collectively referred to herein as the “Exchange Notes.”

All principal accrued under the Exchange Notes is convertible into shares of common stock at the election of the Holder at any time at a fixed conversion price of $1.43 per share (the “Conversion Price”). All principal outstanding under each of the Exchange Notes will be due on April 3, 2018 (the “Maturity Date”). Each of the Exchange Notes bears interest at a rate of 6% per annum, with the interest that would accrue on the initial principal amount of the Exchange Notes during the first 12 months being guaranteed and deemed earned as of the date of issuance. Prior to the Maturity Date, all interest accrued under the Exchange Notes is payable in cash or, if certain conditions are met, payable in shares of common stock at the Company’s option, at a conversion price of $1.34 per share.

Pursuant to the terms of the Third Exchange Note, since the volume-weighted average price of the Company’s common stock was less than the Conversion Price on May 6, 2016, the Company issued an additional 140,000 shares of common stock (the “True-Up Shares”) to Riverside.

As of May 13, 2016, the entire principal amount of the First and Second Exchange Notes, $200,000 of the Third Exchange Note, and the interest related to the First, Second, and Third Exchange Notes has been converted into 1,672,788 shares of common stock leaving the total principal balance outstanding under the Exchange Notes at $800,000.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements for the year ended December 31, 2015 and the notes thereto, along with Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2015, filed separately with the U.S. Securities and Exchange Commission. This discussion and analysis contains forward-looking statements based upon current beliefs, plans, expectations, intentions and projections that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2015, and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q.

Overview

We are a commercial biomaterial company focused on using our silicon nitride ceramic technology platform to develop, manufacture and sell a broad range of medical devices. We currently market spinal fusion products made with our silicon nitride biomaterial technology and are developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty also manufactured from our silicon nitride biomaterial. We believe our silicon nitride technology platform enables us to offer new and transformative products in the orthopedic and other medical device markets. We believe we are the first and only company to use silicon nitride in medical applications. More than 25,000 of our silicon nitride spine products have been implanted in patients.

Biomaterials come in an array of synthetic or natural materials available in a variety of forms that are used in virtually every medical specialty. We believe our silicon nitride biomaterial has superior characteristics compared to commonly used biomaterials in the markets we are targeting, including polyetheretherketone (“PEEK”), which is the most common biomaterial used for interbody spinal fusion products. Specifically, we believe our silicon nitride has the following key attributes: promotion of bone growth; antibacterial properties; superior biocompatibility; hardness, strength and resistance to fracture; resistance to wear; non-corrosive; and superior diagnostic imaging compatibility.

We currently market our Valeo™ family of silicon nitride interbody spinal fusion devices in the United States, Europe and Brazil for use in the cervical and thoracolumbar areas of the spine. We believe our Valeo devices have a number of advantages over existing products due to silicon nitride’s key characteristics, resulting in faster and more effective fusion and reduced risk of infection.

In addition to our silicon nitride-based spinal fusion products, we market a line of non-silicon nitride spinal surgery products which allows us to provide surgeons and hospitals with a more complete solution for spinal procedures. These additional products are complementary to our fusion products and are designed for the treatment of deformity and degenerative spinal procedures. Although our non-silicon nitride products have accounted for approximately 46% and 44% of our product revenues for the quarters ended March 31, 2016 and 2015, respectively, we believe the continued promotion and potential for adoption of our silicon nitride products and product candidates, if approved, provides us the greatest opportunity to grow our business in new and existing markets and achieve our goal to become a leading biomaterial company.

In addition to the markets into which we directly sell our products, we are utilizing our silicon nitride technology platform to expand our current penetration in the spinal fusion market through original equipment manufacturer (“OEM”) and private label partnerships. We also expect to do the same in other markets such as total hip and knee joint replacements, dental, extremities, trauma, and sports medicine. We believe our biomaterial expertise, strong intellectual property, and formulaic manufacturing process will allow us to transition currently available medical device products made of inferior biomaterials and manufacture them using our proprietary silicon nitride formulation and technology platform to improve their characteristics. We believe the OEM and private label partnerships we will continue to develop will lead to an accelerated adoption of silicon nitride for medical applications and offer the Company incremental revenue at improved operating margins as compared to our existing distributor spine sales.

We are also incorporating our silicon nitride technology into components for use in total hip and knee replacement product candidates that we plan on developing in collaboration with a strategic partner. We believe that our silicon nitride total hip and knee product candidates will provide competitive advantages over current products made with traditional biomaterials. We also believe our silicon nitride technology platform can be used for developing products in other markets and have developed prototypes for use in the dental, sports medicine, extremities, and trauma markets. As a result of some of the key characteristics of our silicon nitride, we also believe our coating technology may be used to enhance our metal products as well as commercially available metal spinal fusion, joint replacement and other medical products.

We operate a 30,000 square foot manufacturing facility located at our corporate headquarters in Salt Lake City, Utah, and we are the only vertically integrated silicon nitride medical device manufacturer in the world. We market and sell our products to surgeons and hospitals in the United States and select markets in Europe and South America through an established network of more than 50 independent sales distributors who are managed by our experienced in-house sales and marketing management team.

Recent Developments

Hercules and Riverside Debt Assignment

In April 2016, we entered into an Assignment Agreement with Riverside, and Hercules, pursuant to which Hercules sold $3.0 million of the principal amount outstanding under the Hercules Term Loan to Riverside. For a more detailed description of the Assignment Agreement refer to Note 11 Subsequent Events in the consolidated financial statements of this Report.

Riverside Debt Exchange

In April 2016, we entered into an exchange agreement with Riverside, which resulted in the exchange of $3.0 million of the principal amount outstanding under the Hercules Term Loan held by Riverside for three subordinated convertible promissory notes each in the principal amount of $1.0 million. Pursuant to the terms and conditions of the exchange we offered a warrant to purchase 100,000 shares of the Company’s common stock at a fixed exercise price of $1.62 per share and a warrant to purchase an additional 100,000 shares of the Company’s common stock at a fixed exercise price of $1.66 per share.

All principal accrued under the Exchange Notes is convertible into shares of the Company’s common stock at the election of the Holder at any time at a fixed conversion price of $1.43 per share. All principal outstanding under each of the Exchange Notes will be due on March 3, 2018. Each of the Exchange Notes bears interest at a rate of 6% per annum, with the interest that would accrue on the initial principal amount of the Exchange Notes during the first 12 months being guaranteed and deemed earned as of the date of issuance. Prior to the Maturity Date, all interest accrued under the Exchange Notes is payable in cash or, if certain conditions are met, payable in shares of common stock at the Company’s option, at a conversion price of $1.34 per share.

Each of the First and Second Exchange Warrants will be exercisable commencing on the six month and one day anniversary of the date of issuance and will remain exercisable until the close of business on the five year anniversary of the date of issuance, but not thereafter. If the shares underlying the Exchange Warrants are not registered for resale with the Securities and Exchange Commission, the Exchange Warrants will be exercisable on a cashless basis.

As of May 13, 2016, the entire principal amount of the First and Second Exchange Notes, $0.2 million of the Third Exchange Note, and the interest related to the First, Second, and Third Exchange Notes has been converted into 1,672,788 shares of common stock leaving the total principal balance outstanding under the Exchange Notes at $0.8 million.

For a more detailed description of the Riverside Debt Exchange refer to Note 11 Subsequent Events in the consolidated financial statements of this Report.

Components of our Results of Operations

We manage our business within one reportable segment, which is consistent with how our management reviews our business, makes investment and resource allocation decisions and assesses operating performance.

Product Revenue

We derive our product revenue primarily from the sale of spinal fusion devices and related products used in the treatment of spine disorders. Our product revenue is generated from sales to three types of customers: (1) surgeons and hospitals; (2) stocking distributors; and (3) private label customers. Most of our products are sold on a consignment basis through a network of independent sales distributors; however, we also sell our products to independent stocking distributors and private label customers. Product revenue is recognized when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products has occurred; (3) the selling price of the product is fixed or determinable; and (4) collectability is reasonably assured. We generate the majority of our revenue from the sale of inventory that is consigned to independent sales distributors that sell our products to surgeons and hospitals. For these products, we recognize revenue at the time we are notified the product has been used or implanted and all other revenue recognition criteria have been met. For all other transactions, we recognize revenue when title and risk of loss transfer to the stocking distributor or private label customers, and all other revenue recognition criteria have been met. We generally recognize revenue from sales to stocking distributors and private label customers at the time the product is shipped to the distributor. Stocking distributors, who sell the products to their customers, take title to the products and assume all risks of ownership at time of shipment. Our stocking distributors are obligated to pay within specified terms regardless of when, if ever, they sell the products. Our policy is to classify shipping and handling costs billed to customers as an offset to total shipping expense in the statement of operations, primarily within sales and marketing. In general, our customers do not have any rights of return or exchange.

We believe our product revenue from the sale of our silicon nitride based products will increase due to our sales and marketing efforts and as we introduce new silicon nitride based products into the market and our product revenue from the sale of our non-silicon nitride products to remain flat. We expect that our product revenue will continue to be primarily attributable to sales of our products in the United States.

Cost of Revenue

The expenses that are included in cost of revenue include all direct product costs if we obtained the product from third-party manufacturers and our in-house manufacturing costs for the products we manufacture. We obtain our non-silicon nitride products, including our metal and orthobiologic products, from third-party manufacturers, while we currently manufacture our silicon-nitride products in-house.

Specific provisions for excess or obsolete inventory are also included in cost of revenue. In addition, we pay royalties attributable to the sale of specific products to some of our surgeon advisors that assisted us in the design, regulatory clearance or commercialization of a particular product. These payments are recorded as cost of revenue.

Gross Profit

Our gross profit measures our product revenue relative to our cost of revenue. We expect our gross profit to decrease as we expand the penetration of our silicon nitride technology platform through OEM and private label partnerships.

Research and Development Expenses

Our net research and development costs are expensed as incurred. Research and development costs consist of engineering, product development, clinical trials, test-part manufacturing, testing, developing and validating the manufacturing process, manufacturing, facility and regulatory-related costs. Research and development expenses also include employee compensation, employee and non-employee stock-based compensation, supplies and materials, consultant services, and travel and facilities expenses related to research activities. To the extent that certain research and development expenses are directly related to our manufactured products, such expenses and related overhead costs are allocated to inventory.

We expect to incur additional research and development costs as we continue to develop new spinal fusion products, our product candidates for total joint replacements, such as our total hip replacement product candidate, and our silicon nitride-coated metals which may increase our total research and development expenses.

Sales and Marketing Expenses

Sales and marketing expenses consist of salaries, benefits and other related costs, including stock-based compensation, for personnel employed in sales, marketing, medical education and training. In addition, our sales and marketing expenses include commissions and bonuses, generally based on a percentage of sales, to our sales managers and independent sales distributors. We provide our products in kits or banks that consist of a range of device sizes and separate instruments sets necessary to perform the surgical procedure. We generally consign our instruments to our distributors or our hospital customers that purchase the device used in spinal fusion surgery. Our sales and marketing expenses include depreciation of the surgical instruments.

We expect our sales and marketing expenses will remain flat or slightly decline due to the cost saving measures implemented during the first quarter. Additionally, we expect our commissions to increase in absolute terms over time but remain approximately the same or decrease as a percentage of product revenue.

General and Administrative Expenses

General and administrative expenses primarily consist of salaries, benefits and other related costs, including stock-based compensation, for certain members of our executive team and other personnel employed in finance, legal, compliance, administrative, information technology, customer service, executive and human resource departments. General and administrative expenses include allocated facility expenses, related travel expenses and professional fees for accounting and legal services.

We expect our general and administrative expenses to remain relatively flat.

RESULTS OF OPERATIONS

The following is a tabular presentation of our condensed consolidated operating results for the three months ended March 31, 2016 and 2015 (in thousands):

	Three Months Ended March 31,
	2016		2015		$ Change		% Change
Product revenue	$	4,173	$	4,743	$	(570)		(12)%
Costs of revenue		893		1,522		(629)		(41)%
Gross profit		3,280		3,221		59		2%
Operating expenses:
Research and development		1,608		1,843		(235)		(13)%
General and administrative		1,562		2,027		(465)		(23)%
Sales and marketing		2,594		3,357		(763)		(23)%
Total operating expenses		5,764		7,227		(1,463)		(20)%
Loss from operations		(2,484)		(4,006)		1,522		38%
Other income (expense), net		(904)		(1,375)		471		34%
Net loss before income taxes		(3,388)		(5,381)		1,993		37%
Provision for income taxes		-		-		-
Net loss	$	(3,388)	$	(5,381)	$	1,993		37%

Product Revenue

The following table sets forth our product revenue from sales of the indicated product category for the three months ended March 31, 2016 and 2015 (in thousands):

	Three Months Ended March 31,
	2016		2015		$ Change		% Change
Silicon Nitride	$	2,238	$	2,658	$	(420)		(16)	%
Non-Silicon Nitride		1,935		2,085		(150)		(7)	%
Total product revenue	$	4,173	$	4,743	$	(570)		(12)	%

For the three months ended March 31, 2016, total product revenue was $4.2 million as compared to $4.7 million in the same period 2015, a decrease of $0.5 million, or 12%. This decrease was due to lower private label sales during the quarter and weaker than expected commercial sales in a key geographic area during the implementation of our commercial sales expansion strategy. The decrease in revenue for the three months ended March 31, 2016 was also attributable, in part, to continued market pricing pressure and hospital vendor consolidation.

The following table sets forth, for the periods indicated, our product revenue by geographic area (in thousands):

	Three Months Ended March 31,
	2016		2015		$ Change		% Change
Domestic	$	4,009	$	4,732	$	(723)		(15)%
International		164		11		153		1,391%
Total product revenue	$	4,173	$	4,743	$	(570)		(12)%

International revenue increased $0.2 million during the three months ended March 31, 2016 as compared to the same periods in 2015, primarily as a result of increased sales of our silicon nitride products in Brazil and Europe.

Cost of Revenue and Gross Profit

For the three months ended March 31, 2016, our cost of revenue decreased $0.6 million, or 41%, as compared to the same period in 2015. The decrease was primarily due to the decline in sales and the moratorium on the medical device excise tax in addition to receiving a refund for the medical device excise tax. Furthermore, there was minimal private label revenue during the three months ended March 31, 2016 resulting in increased gross profit during the three months ended March 31, 2016 as compared to the same period in 2015.

Research and Development Expenses

For the three months ended March 31, 2016, research and development expenses decreased $0.2 million, or 13%, as compared to the same period in 2015. This decrease was primarily attributable to a $0.5 million decrease in personnel related expenses and a $0.1 million decrease of stock compensation expense. These improvements were offset by an increase of $0.3 million of costs that were not capitalized to inventory due to lower inventory production rates in 2016 as compared to 2015.

General and Administrative Expenses

For the three months ended March 31, 2016, general and administrative expenses decreased $0.5 million, or 23%, as compared to the same period in 2015. This decrease was primarily attributable to a $0.3 million decrease in personnel related expenses and a $0.3 million decrease in stock compensation expense. These improvements were offset, in part, by a $0.1 million increase in patent related expenses during the quarter.

Sales and Marketing Expenses

For the three months ended March 31, 2016, sales and marketing expenses decreased $0.8 million, or 23%, as compared to the same period in 2015. This decrease was primarily attributable to a $0.4 million decrease in personnel related expenses, a decrease of $0.1 million of stock compensation expense, and a decrease of $0.3 million in commissions due to lower sales.

Other Income (Expense), Net

For the three months ended March 31, 2016, other expense decreased $0.5 million, or 34%, as compared to the same period in 2015. This decrease was primarily due to a net decrease of $0.2 million in the change in fair value of derivative liabilities due to the significant reduction in the balance of our derivative liabilities and a decrease of $0.2 million in interest expense as a result of lower debt balances. Additionally, there was a decrease of $0.1 million from a loss on extinguishment of debt during three months ended March 31, 2015.

Liquidity and Capital Resources

For the three months ended March 31, 2016 and 2015, we incurred a net loss of $3.4 million and $5.4 million, respectively, and used cash in operations of $1.5 million and $3.0 million, respectively. We have an accumulated deficit of $199.9 million as of March 31, 2016. To date, our operations have been principally financed from proceeds from the issuance of convertible preferred stock and common stock, convertible debt and bank debt and, to a lesser extent, cash generated from product sales. As of March 31, 2016, we had approximately $7.9 million in cash and cash equivalents.

We will need to, from time-to-time, seek additional financing through the issuance of common stock and/or debt, to satisfy our debt obligations and financial covenants, meet our working capital requirements, make continued investment in research and development and make capital expenditures needed for us to maintain and expand our business. We anticipate we will need to obtain additional funding early in the third quarter of 2016 to maintain compliance with the financial and liquidity covenants related to the Hercules Term Loan. If the Company is unable to access additional funds prior to becoming non-compliant with the financial and liquidity covenants related to the Hercules Term Loan, the entire remaining balance of the debt under the Hercules Term Loan could become immediately due and payable at the option of Hercules Technology. We may not be able to obtain additional financing on terms favorable to us, if at all. It is also possible that we may allocate significant amounts of capital toward solutions or technologies for which market demand is lower than anticipated and, as a result, abandon such efforts. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, or if we expend capital on projects that are not successful, our ability to continue to support our business growth and to respond to business challenges could be significantly limited, or we may even have to scale back our operations. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our common stock

Going Concern

Our ability to access capital when needed is not assured and, if not achieved on a timely basis, will materially harm our business, financial condition and results of operations. These uncertainties create substantial doubt about our ability to continue as a going concern. Our independent registered public accounting firm included an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern in their report on our annual financial statements for the fiscal year ended December 31, 2015. The financial information throughout this quarterly report have been prepared on a basis which assumes that we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. This financial information and statements do not include any adjustments that may result from the outcome of this uncertainty.

Cash Flows

The following table summarizes, for the periods indicated, cash flows from operating, investing and financing activities (in thousands):

	Three Months Ended March 31,
	2016		2015
Net cash used in operating activities	$	(1,465)	$	(2,971)
Net cash used in investing activities		(243)		(274)
Net cash used in financing activities		(1,834)		(120)
Net cash used	$	(3,542)	$	(3,365)

Net Cash Used in Operating Activities

Net cash used in operating activities decreased $1.5 million to $1.5 million during the three months ended March 31, 2016, from $3.0 million for the same period in 2015. The decrease in cash used in operating activities during 2016 was primarily due to an overall decrease of $1.1 million in operational expenditures as we continue to focus our efforts to reduce costs. Additionally, accounts receivable decreased $0.8 million, which was offset by an increase of $0.4 million in accounts payable and prepaid expenses.

Net Cash Used in Investing Activities

Net cash used in investing activities during the three months ended March 31, 2016 was consistent with the level of cash used in the same period 2015. This cash was used to replenish our inventory of instrumentation.

Net Cash Used in Financing Activities

Net cash used in financing activities was $1.8 million during the three months ended March 31, 2016, compared to $0.1 million used during the same period in 2015. This increase in net cash used by financing activities in 2016 was primarily attributable to principal payments made on our notes payable.

Indebtedness

Hercules Term Loan

On June 30, 2014, we entered into a Loan and Security Agreement with Hercules which provided the Company with a $20 million term loan. The Hercules Term Loan matures on January 1, 2018. The Hercules Term Loan included a $200,000 closing fee, which was paid to Hercules on the closing date of the loan. The closing fee was recorded as a debt discount and is being amortized to interest expense over the life of the loan. The Hercules Term Loan also includes a non-refundable final payment fee of $1.7 million. The final payment fee is being accrued and recorded to interest expense over the life of the loan. The Hercules Term Loan bears interest at the rate of the greater of either (i) the prime rate plus 9.2%, and (ii) 12.5%, which was 12.7% at March 31, 2016. Interest accrues from the closing date of the loan and interest payments are due monthly. Principal payments commenced August 1, 2015 and are to be made in 30 equal installments of approximately $700,000, with the remainder due at maturity. The Company’s obligations to Hercules are secured by a first priority security interest in substantially all of its assets, including intellectual property. The Hercules Term Loan contains certain covenants related to restrictions on payments to certain Company affiliates and financial reporting requirements.

On September 8, 2015, we entered into a Consent and First Amendment to Loan and Security Agreement with Hercules. The Amendment modified the liquidity covenant to reduce the minimum cash balance required by $500,000 for every $1.0 million paid in principal to a minimum of $2.5 million. The minimum cash and cash equivalents balance required to maintain compliance with the minimum liquidity covenant at March 31, 2016 was $7.0 million. Although the Company was in compliance with the liquidity covenant at March 31, 2016, we anticipate that we will be non-compliant with the liquidity covenant early in the third quarter of 2016 if additional financing is not obtained or the loan is not restructured, and has therefore classified the entire obligation as a current liability.

As discussed previously in Recent Developments under the headings “Hercules and Riverside Debt Assignment”, Hercules sold $3.0 million in principal of its term loan to Riverside during April 2016. Following the assignment, the monthly principal payments were reduced to approximately $500,000. See additional information above in Recent Developments under the headings, “Hercules and Riverside Debt Assignment” and “Riverside Debt Exchange.”

Magna Note

The outstanding principal amount of the Magna Note was $763,000 at March 31, 2016. The Magna Note matures on August 11, 2016, and accrues interest at an annual rate of 6.0%. We have agreed to pay an additional $0.8 million to redeem in full the remaining principal balance and interest if the Company receives gross proceeds of $3.6 million from the sale of equity securities.

Riverside Debt Exchange

For a description of our indebtedness to Riverside, see information above under the heading in Recent Developments “Riverside Debt Exchange.”

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as defined in Item 303(a)(4) of Regulation S-K.

Critical Accounting Policies and Estimates

A summary of our significant accounting policies and estimates is discussed in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in Note 1 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2015. There have been no material changes to those policies during the three months ended March 31, 2016. The preparation of the financial statements in accordance with U.S. generally accepted accounting principles requires us to make judgments, estimates and assumptions regarding uncertainties that affect the reported amounts of assets and liabilities. Significant areas of uncertainty that require judgments, estimates and assumptions include the accounting for income taxes and other contingencies as well as valuation of derivative liabilities, asset impairment and collectability of accounts receivable. We use historical and other information that we consider to be relevant to make these judgments and estimates. However, actual results may differ from those estimates and assumptions that are used to prepare our financial statements.

New Accounting Pronouncements

See discussion under Note 1, Organization and Summary of Significant Accounting Policies, to the Condensed Consolidated Financial Statements included in Item 1 of Part I of this Quarterly Report on Form 10-Q, for information on new accounting pronouncements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

This Report includes the certifications of our Chief Executive Officer and Principal Accounting Officer required by Rule 13a-14 of the Securities Exchange Act of 1934 (the “Exchange Act”). See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations referred to in those certifications.

Evaluation of Disclosure Controls and Procedures

Our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in rules and forms adopted by the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Principal Accounting Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

In connection with the preparation of this report, our management, under the supervision and with the participation of our Chief Executive Officer and our Principal Accounting Officer, evaluated the effectiveness of our disclosure controls and procedures. Based on that evaluation, our Chief Executive Officer and Principal Financial and Accounting Officer have concluded that our disclosure controls and procedures were effective as of March 31, 2016.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the first quarter of 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

ITEM 1. LEGAL PROCEEDINGS

On April 1, 2016, Hampshire MedTech Partners II, GP (“Hampshire GP”) filed suit against us in the Travis County, Texas 200th Judicial District Court relating to a Warrant to Purchase Shares of Common Stock issued by us to Hampshire MedTech Partners II, LP (“Hampshire LP”) on November 6, 2014 (the “Warrant”). Hampshire GP alleges that as a result of a subsequent financing we breached the anti-dilution provision of the Warrant by failing to increase the number of shares subject to the Warrant as well as failing to reduce the exercise price of the Warrant. Hampshire GP seeks damages in excess of $1,000,000. We have not yet answered Hampshire GP’s complaint and we intend to vigorously defend ourselves in this suit.

We are not aware of any other pending or threatened legal proceeding against us that could have a material adverse effect on our business, operating results or financial condition. The medical device industry is characterized by frequent claims and litigation, including claims regarding patent and other intellectual property rights as well as improper hiring practices. As a result, we may be involved in various additional legal proceedings from time to time.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Unregistered Sales of Equity Securities

From, April 6, 2016 to May 13, 2016 the Company issued Riverside Merchant Partners, LLC (“Riverside”) a total of 1,812,788 shares of common stock in connection with the conversion of $2.4 million in convertible debt principal and interest held by Riverside. The recipient is an accredited investor and the issuance was exempt from registration under the Securities Act of 1933 in reliance on exemptions provided by Section 4(2) of the Act.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit Number	Exhibit Description	Filed Herewith	Incorporated by Reference herein from Form or Schedule	Filing Date	SEC File/ Reg. Number

4.1	Common Stock Purchase Warrant		Form 8-K	04/05/2016	001-33624

10.1	Assignment and Second Amendment to Loan and Security Agreement, dated April 4, 2016, by and among the Company Riverside Merchant Partners, LLC, Hercules Technology III, L.P. and Hercules Capital, Inc., the financial institutions signatory thereto, Amedica Corporation, and the guarantors signatory thereto		Form 8-K	04/05/2016	001-33624

10.2	Exchange Agreement dated April 4, 2016, by and among Amedica Corporation and Riverside Merchant Partners, LLC		Form 8-K	04/05/2016	001-33624

10.3	Subordinated Convertible Promissory Note, dated April 4, 2016, by and among Amedica Corporation and Riverside Merchant Partners, LLC		Form 8-K	04/05/2016	001-33624

31.1	Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	X

31.2	Certificate of the Principal Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X

101.INS	XBRL Instance Document	X

101.SCH	XBRL Taxonomy Extension Schema Document	X

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document	X

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document	X

101.LAB	XBRL Taxonomy Extension Label Linkbase Document	X

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document	X

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	AMEDICA CORPORATION

Date: May 13, 2016	/s/ B. Sonny Bal
	B. Sonny Bal
	Chief Executive Officer (Principal Executive Officer)

Date: May 13, 2016	/s/ Ty A. Lombardi
	Ty A. Lombardi
	Chief Financial Officer (Principal Financial and Accounting Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, B. Sonny Bal, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Amedica Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 13, 2016	By:	/s/ B. Sonny Bal
		B. Sonny Bal
		Chief Executive Officer

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Ty A. Lombardi, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Amedica Corporation;

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 13, 2016	By:	/s/ Ty A. Lombardi
		Ty A. Lombardi
		Chief Financial Officer

EX-32 4 ex32.htm

Exhibit 32

CERTIFICATIONS UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Amedica Corporation., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The quarterly report for the quarter ended March 31, 2016 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 13, 2016	By:	/s/ B. Sonny Bal
		B. Sonny Bal
		Chief Executive Officer

Date: May 13, 2016	By:	/s/ Ty A. Lombardi
		Ty A. Lombardi
		Chief Financial Officer

EX-101.INS 5 amda-20160331.xml XBRL INSTANCE FILE 0001269026 2016-01-01 2016-03-31 0001269026 2016-05-13 0001269026 2016-03-31 0001269026 2014-12-31 0001269026 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0001269026 us-gaap:CustomerRelationshipsMember 2015-12-31 0001269026 us-gaap:DevelopedTechnologyRightsMember 2015-12-31 0001269026 AMDA:OtherPatentsAndPatentApplicationsMember 2015-12-31 0001269026 us-gaap:TrademarksMember 2015-12-31 0001269026 us-gaap:CustomerRelationshipsMember 2016-03-31 0001269026 us-gaap:DevelopedTechnologyRightsMember 2016-03-31 0001269026 AMDA:OtherPatentsAndPatentApplicationsMember 2016-03-31 0001269026 us-gaap:TrademarksMember 2016-03-31 0001269026 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember AMDA:CommonStockWarrantsMember 2015-12-31 0001269026 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember AMDA:CommonStockWarrantsMember 2015-12-31 0001269026 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember AMDA:CommonStockWarrantsMember 2015-12-31 0001269026 us-gaap:FairValueMeasurementsRecurringMember AMDA:CommonStockWarrantsMember 2015-12-31 0001269026 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember AMDA:CommonStockWarrantsMember 2016-03-31 0001269026 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember AMDA:CommonStockWarrantsMember 2016-03-31 0001269026 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember AMDA:CommonStockWarrantsMember 2016-03-31 0001269026 us-gaap:FairValueMeasurementsRecurringMember AMDA:CommonStockWarrantsMember 2016-03-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:CommonStockWarrantsMember 2016-01-01 2016-03-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:PreferredStockWarrantsMember 2016-01-01 2016-03-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:ConverisonFeatureOfNotesMember 2016-01-01 2016-03-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2016-01-01 2016-03-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:CommonStockWarrantsMember 2015-01-01 2015-03-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:PreferredStockWarrantsMember 2015-01-01 2015-03-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:ConverisonFeatureOfNotesMember 2015-01-01 2015-03-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2015-01-01 2015-03-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:CommonStockWarrantsMember 2014-12-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:PreferredStockWarrantsMember 2014-12-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2014-12-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:ConverisonFeatureOfNotesMember 2014-12-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:CommonStockWarrantsMember 2015-12-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:PreferredStockWarrantsMember 2015-12-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:ConverisonFeatureOfNotesMember 2015-12-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2015-12-31 0001269026 AMDA:HerculesTermLoanMember us-gaap:ConvertibleNotesPayableMember 2016-03-31 0001269026 us-gaap:ConvertibleNotesPayableMember 2016-03-31 0001269026 AMDA:HerculesTermLoanMember 2016-03-31 0001269026 AMDA:HerculesTermLoanMember 2015-12-31 0001269026 AMDA:MagnaNoteMember 2015-12-31 0001269026 AMDA:HerculesTechnologyCapitalIncMember AMDA:LoanAndSecurityAgreementMember 2014-06-30 0001269026 AMDA:LoanAndSecurityAgreementMember AMDA:HerculesTechnologyCapitalIncMember 2014-06-29 2014-06-30 0001269026 AMDA:HerculesTermLoanMember us-gaap:PrimeRateMember 2016-03-31 0001269026 AMDA:HerculesTermLoanMember us-gaap:PrimeRateMember 2014-06-30 0001269026 AMDA:HerculesTermLoanMember 2016-01-01 2016-03-31 0001269026 AMDA:HerculesTermLoanMember AMDA:FirstAmendmentToLoanAndSecurityAgreementMember 2015-09-07 2015-09-08 0001269026 AMDA:HerculesTermLoanMember AMDA:FirstAmendmentToLoanAndSecurityAgreementMember us-gaap:MinimumMember 2015-09-08 0001269026 AMDA:MagnaNoteMember 2016-03-31 0001269026 AMDA:TwoThouandTwelvePlanMember 2016-01-31 0001269026 AMDA:TwoThouandTwelvePlanMember 2016-03-31 0001269026 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-03-31 0001269026 AMDA:CostOfRevenueMember 2016-01-01 2016-03-31 0001269026 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0001269026 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001269026 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-03-31 0001269026 AMDA:CapitalizedIntoInventoryMember 2016-01-01 2016-03-31 0001269026 AMDA:CostOfRevenueMember 2015-01-01 2015-03-31 0001269026 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-03-31 0001269026 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0001269026 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-03-31 0001269026 AMDA:CapitalizedIntoInventoryMember 2015-01-01 2015-03-31 0001269026 us-gaap:EmployeeStockOptionMember 2016-03-31 0001269026 us-gaap:SubsequentEventMember AMDA:AssignmentAgreementMember AMDA:RiversideMerchantPartnersLLCMember 2016-04-03 2016-04-04 0001269026 AMDA:SeriesAWarrantsMember 2015-09-30 0001269026 AMDA:MagnaNoteMember us-gaap:ConvertibleNotesPayableMember 2016-03-31 0001269026 AMDA:TwoThouandTwelvePlanMember 2016-01-01 2016-01-31 0001269026 2015-01-01 2015-12-31 0001269026 2015-01-01 2015-03-31 0001269026 2015-12-31 0001269026 2015-03-31 0001269026 AMDA:HerculesTermLoanMember us-gaap:MinimumMember 2016-03-31 0001269026 AMDA:RiversideMerchantPartnersLLCMember 2016-03-31 0001269026 us-gaap:ScenarioPreviouslyReportedMember 2015-12-31 0001269026 us-gaap:RestatementAdjustmentMember 2015-12-31 0001269026 us-gaap:CommonStockMember 2015-01-01 2015-03-31 0001269026 us-gaap:CommonStockMember 2016-01-01 2016-03-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:CommonStockWarrantsMember 2016-03-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:PreferredStockWarrantsMember 2016-03-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:ConverisonFeatureOfNotesMember 2016-03-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2016-03-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:CommonStockWarrantsMember 2015-03-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:PreferredStockWarrantsMember 2015-03-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:ConverisonFeatureOfNotesMember 2015-03-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2015-03-31 0001269026 AMDA:HerculesTermLoanMember 2014-06-30 0001269026 AMDA:SeriesAWarrantsMember 2015-09-01 2015-09-30 0001269026 AMDA:SeriesAWarrantsMember 2016-03-31 0001269026 AMDA:HerculesTermLoanMember AMDA:FirstAmendmentToLoanAndSecurityAgreementMember 2015-09-08 0001269026 AMDA:HerculesTermLoanMember AMDA:FirstAmendmentToLoanAndSecurityAgreementMember 2016-03-31 0001269026 AMDA:RiversideMerchantPartnersLLCMember AMDA:HerculesTermLoanMember 2016-03-31 0001269026 AMDA:SecuritiesPurchaseAgreementMember AMDA:MagnaNoteMember 2016-03-31 0001269026 AMDA:SecuritiesPurchaseAgreementMember AMDA:MagnaNoteMember 2014-08-31 0001269026 AMDA:SecuritiesPurchaseAgreementMember AMDA:MagnaNoteMember 2016-01-01 2016-03-31 0001269026 us-gaap:SubsequentEventMember AMDA:AssignmentAgreementMember AMDA:RiversideMerchantPartnersLLCMember 2016-04-04 0001269026 us-gaap:SubsequentEventMember AMDA:AssignmentAgreementMember AMDA:RiversideMerchantPartnersLLCMember 2016-04-17 2016-04-18 0001269026 us-gaap:SubsequentEventMember AMDA:AssignmentAgreementMember AMDA:RiversideMerchantPartnersLLCMember 2016-04-26 2016-04-27 0001269026 us-gaap:SubsequentEventMember AMDA:ExchangeAgreementMember AMDA:RiversideMerchantPartnersLLCMember 2016-04-04 0001269026 us-gaap:SubsequentEventMember AMDA:ExchangeAgreementMember AMDA:RiversideMerchantPartnersLLCMember 2016-04-03 2016-04-04 0001269026 us-gaap:SubsequentEventMember AMDA:ExchangeAgreementMember AMDA:RiversideMerchantPartnersLLCMember AMDA:HerculesTermLoanMember 2016-04-04 0001269026 us-gaap:SubsequentEventMember AMDA:ExchangeAgreementMember AMDA:RiversideMerchantPartnersLLCMember 2016-04-18 0001269026 us-gaap:SubsequentEventMember AMDA:ExchangeAgreementMember AMDA:RiversideMerchantPartnersLLCMember 2016-04-26 2016-04-27 0001269026 us-gaap:SubsequentEventMember AMDA:ExchangeAgreementMember AMDA:RiversideMerchantPartnersLLCMember 2016-04-27 0001269026 us-gaap:SubsequentEventMember AMDA:ExchangeAgreementMember 2016-04-04 0001269026 us-gaap:SubsequentEventMember AMDA:ExchangeAgreementMember 2016-04-03 2016-04-04 0001269026 us-gaap:SubsequentEventMember AMDA:ThirdExchangeNoteMember AMDA:RiversideMerchantPartnersLLCMember 2016-05-05 2016-05-06 0001269026 us-gaap:SubsequentEventMember AMDA:FirstExchangeNoteMember AMDA:RiversideMerchantPartnersLLCMember 2016-05-12 2016-05-13 0001269026 us-gaap:SubsequentEventMember AMDA:ThirdExchangeNoteMember AMDA:RiversideMerchantPartnersLLCMember 2016-05-13 0001269026 2014-11-05 2014-11-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure AMEDICA Corp 10-Q 2016-03-31 false --12-31 Smaller Reporting Company 13236071

18988000

23505000

705000

229000

821000

-592000

1848000

2660000

7943000

18247000

11485000

14882000

7000000

31081000

35862000

35000

6163000

3562000

3687000

2333000

2472000

18970000

20429000

14785000

16365000

16957000

-592000

3203000

3421000

982000

643000

604000

598000

604000

598000

169000

171000

405000

432000

31081000

35862000

-199925000

-196537000

210744000

210660000

114000

109000

28000

49000

0.01

250000000

4173000

4743000

893000

1522000

3280000

3221000

1608000

1843000

1562000

2027000

2594000

3357000

5764000

7227000

-2484000

-4006000

-79000

-11000

-435000

612000

177000

-177000

-16000

-904000

-1375000

-3388000

-5381000

-0.30

-3.00

11193250

1795296

10933000

14232000

536388

2000000

202000

2000000

1000000

200000

140000

1672788

-3388000

-5381000

-20000

373000 326000

4000

-3000

88000

592000

405000

551000

5000

125000

389000

428000

-1465000

-2971000

-64000

200000

-263000

-293000

476000

330000

-813000

35000

-243000

-274000

16000

3000

259000

277000

1834000

120000

-1834000

-120000

-3542000

-3365000

739000

507000

548000

3400000

3800000

375000

501000

834000

9587000

3990000

4685000

562000

350000

3990000

4685000

562000

350000

9587000

6025000

5900000

100000

179000

723000

-11358000

-13970000

-2612000

-598000

-604000

-10200000

-3045000

-13245000

0.0106

0.0171

P3Y6M18D

P3Y8M12D

0.00

1.37

1.19

563000

867000

359000

683000

478000

515000

237000

222000

922000 783000

644000

351000

5787000

6550000

763000

8643000

788000

14785000

15218000

15981000

14032000

15631000

734000

753000

763000

16365000

15981000

15218000

17051000

763000

20000000

500000

763000

17814000

3000000

1000000

7000000

3000000

763000

3500000

1000000

800000

15981000 17814000

1196000

1186000

1420000

29000

10000

1449000

1196000

-1449000

2018-01-01

2016-08-11

2018-04-03

200000

1700000

0.127

0.125

0.092

0.060

0.06

700000

1000000

23004

90000

4000

29000

40000

15000

2000

29000

122000

328000

142000

39000

660000

121675

112373

74859

119112

35.95

41.53

1.69

60.65

36.50

0.0186

0.0162

P6Y3M18D

0.00

0.65

0.46

435000

P1Y8M12D

900000

1100000

1. Organization and Summary of Significant Accounting Policies   Organization   Amedica Corporation (Amedica or the Company) was incorporated in the state of Delaware on December 10, 1996. Amedica is a commercial-stage biomaterials company focused on using its silicon nitride technology platform to develop, manufacture, and commercialize a broad range of medical devices. The Company believes it is the first and only manufacturer to use silicon nitride in medical applications. The Company acquired US Spine, Inc. (US Spine), a Delaware spinal products corporation with operations in Florida, on September 20, 2010. The Companys products are sold primarily in the United States.   Basis of Presentation   These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (SEC). Such rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Companys Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 23, 2016. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016. The Companys significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2015.   In accordance with the adoption of Accounting Standards Update (ASU) 2015-03, the Companys debt issuance costs have been reclassified to be presented in the Condensed Consolidated Balance Sheets as a direct reduction from the debt liability rather than as an asset.   The following is a reconciliation of the effect of these reclassifications on the Companys Condensed Consolidated Balance Sheet at December 31, 2015 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">As Reported</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Adjustments</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">As Revised</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Assets:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 58%; padding-left: 10pt; line-height: 115%">Prepaid expenses and other current assets</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">821</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(592)</td> <td style="width: 1%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">229</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Liabilities:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Current portion of long-term debt</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">16,957</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(592)</td> <td> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">16,365</td> <td style="line-height: 115%"> </td></tr> </table>   Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Some of the more significant estimates relate to inventory, stock-based compensation, long-lived and intangible assets and the liability for preferred stock and common stock warrants.   Liquidity and Capital Resources   For the three months ended March 31, 2016 and 2015, the Company incurred a net loss of $3.4 million and $5.4 million, respectively, and used cash in operations of $1.5 million and $3 million, respectively. The Company had an accumulated deficit of $199.9 million and $196.5 million at March 31, 2016 and December 31, 2015, respectively. To date, the Companys operations have been principally financed from proceeds from the issuance of preferred and common stock, convertible debt and bank debt and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations through 2016.   As discussed further in Note 7, the Company has entered into a term loan with Hercules Technology Growth Capital, Inc. (Hercules Technology), as administrative and collateral agent for the lenders thereunder and as lender, and Hercules Technology III, LP, (HT III and, together with Hercules Technology, Hercules) as lender (the Hercules Term Loan). The Hercules Term Loan has a liquidity covenant that requires the Company to maintain a cash balance of not less than $7.0 million at March 31, 2016. At March 31, 2016, the Companys cash balance was approximately $7.9 million. The Company anticipates that it will need to refinance the note or obtain additional funding early in the third quarter of 2016 to maintain compliance through 2016 with the liquidity covenant related to the Hercules Term Loan. However, if the Company is unable to refinance the note or access additional funds prior to becoming non-compliant with the financial and liquidity covenants related to the Hercules Term Loan, the entire remaining balance of the debt under the Hercules Term Loan could become immediately due and payable at the option of the lender. Although the Company is seeking to refinance the note or obtain additional financing, additional funding may not be available to the Company on favorable or acceptable terms, or at all. Any additional equity financing, if available to the Company, will most likely be dilutive to its current stockholders, and debt financing, if available, may involve more restrictive covenants. The Companys ability to access capital when needed is not assured and, if not achieved on a timely basis, will materially harm its business, financial condition and results of operations. These uncertainties create substantial doubt about the Companys ability to continue as a going concern. No adjustment has been made to our financial statements as a result of this uncertainty.   See Note 11. Subsequent Events for further discussion with respect to the assignment of $3.0 million of the principal balance of the Hercules Term Loan to Riverside Merchant Partners, LLC (Riverside) and the subsequent agreement between the Company and Riverside to exchange the $3.0 million of the Hercules Term Loan held by Riverside for subordinated convertible promissory notes in the aggregate principal amount of $3.0 million.   Significant Accounting Policies   There have been no significant changes to the Companys significant accounting policies as described in the Companys Annual Report on Form 10-K for the year ended December 31, 2015.   New Accounting Pronouncements   In March 2016 the Financial Accounting Standards Board (FASB) updated the accounting guidance related to stock compensation. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company is still evaluating the impact that this standard will have on its consolidated financial statements.   In February 2016, the FASB updated the accounting guidance related to leases as part of a joint project with the International Accounting Standards Board (IASB) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, a lessee will be required to recognize assets and liabilities for capital and operating leases with lease terms of more than 12 months. Additionally, this ASU will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases, including qualitative and quantitative requirements. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the potential impact this new standard may have on its financial statements.   In August 2014, the FASB updated the accounting guidance related to disclosure of uncertainties about an entitys ability to continue as a going concern. The new standard provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. It requires management to perform interim and annual assessments of an entitys ability to continue as a going concern. The new standard is effective for annual periods ending after December 15, 2016, and interim periods thereafter. Early adoption is permitted. The impact on the Companys financial statements of adopting the new standard is currently being assessed by management.   In May 2014, the FASB updated the accounting guidance related to revenue from contracts with customers, which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle is that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The standard defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, and shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is evaluating the potential impact of this adoption on its consolidated financial statements.

3. Inventories   The components of inventory were as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 115%">Raw materials</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">788</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">819</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">WIP</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">229</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">235</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Finished Goods</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">7,475</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">8,077</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total inventory</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">8,492</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">9,131</td> <td style="line-height: 115%"> </td></tr> </table>   Finished goods include consigned inventory in the amounts of approximately $3.4 million and $3.8 million as of March 31, 2016 and December 31, 2015, respectively.

4. Intangible Assets   Intangible assets consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 115%">Customer relationships</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 18%; text-align: right; line-height: 115%">3,990</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 18%; text-align: right; line-height: 115%">3,990</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Developed technology</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,685</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,685</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Other patents and patent applications</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">562</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">562</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Trademarks</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">350</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">350</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Total intangibles</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">9,587</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">9,587</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Less accumulated amortization</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(6,025)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(5,900)</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Total intangibles net of amortization</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,562</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,687</td> <td style="line-height: 115%"> </td></tr> </table>   Based on the recorded intangibles at March 31, 2016, the estimated amortization expense is expected to be $375,000 during the remainder of 2016 and approximately $501,000 per year through 2020 and $834,000 thereafter.

5. Fair Value Measurements   Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis   The Company measures and records certain financial instruments at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; line-height: 115%"> </td> <td style="width: 43px; line-height: 115%">Level 1</td> <td nowrap="nowrap" style="width: 12px; line-height: 115%"> - </td> <td style="text-align: justify; line-height: 115%">quoted market prices for identical assets or liabilities in active markets.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="line-height: 115%">Level 2</td> <td nowrap="nowrap" style="line-height: 115%"> - </td> <td style="text-align: justify; line-height: 115%">observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="line-height: 115%">Level 3</td> <td nowrap="nowrap" style="line-height: 115%"> - </td> <td style="text-align: justify; line-height: 115%">unobservable inputs reflecting managements assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</td></tr> </table>   The Company classifies assets and liabilities measured at fair value in their entirety based on the lowest level of input that is significant to their fair value measurement. No financial assets were measured on a recurring basis at March 31, 2016 and December 31, 2015. The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy at March 31, 2016 and December 31, 2015:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Fair Value Measurements at March 31, 2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%">Description</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 1</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Derivative liability</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-left: 10pt; line-height: 115%">Common stock warrants</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">604</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">604</td> <td style="width: 1%; line-height: 115%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Fair Value Measurements at December 31, 2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%">Description</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 1</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Derivative liability</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-left: 10pt; line-height: 115%">Common stock warrants</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">598</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">598</td> <td style="width: 1%; line-height: 115%"> </td></tr> </table>   The Company did not have any transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy during the three months ended March 31, 2016 and 2015. The following table presents a reconciliation of the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2016 and 2015:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Common Stock Warrants</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Preferred Stock Warrants</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Conversion Feature of Notes</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total Derivative Liability</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%; line-height: 115%">Balance at December 31, 2014</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">(11,358)</td> <td style="width: 1%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">(2,612)</td> <td style="width: 1%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">(13,970)</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Decrease in liability due to debt conversions</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">179</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">179</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; text-align: justify; line-height: 115%">Decrease in liability due to warrants being exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">723</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">723</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Change in fair value</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">435</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(612)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(177)</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Balance at March 31, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(10,200)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(3,045)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(13,245)</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Balance at December 31, 2015</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(598)</td> <td> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(598)</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-align: justify; line-height: 115%">Increase in fair value included in earnings, as other income</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(6)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(6)</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Balance at March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(604)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(604)</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Common Stock Warrants   The Company has issued certain warrants to purchase shares of common stock, which are considered mark-to-market liabilities and are re-measured to fair value at each reporting period in accordance with accounting guidance.   The assumptions used in estimating the common stock warrant liability at March 31, 2016 and December 31, 2015 were as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31,2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 115%">Weighted-average risk free interest rate</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 18%; text-align: right; line-height: 115%">1.06%</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 18%; text-align: right; line-height: 115%">1.71%</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Weighted-average expected life (in years)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.55</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.7</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expected dividend yield</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0%</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Weighted average expected volatility</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">137%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">119%</td> <td style="line-height: 115%"> </td></tr> </table>   Other Financial Instruments   The Companys recorded values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The recorded value of notes payable approximates the fair value as the interest rate approximates market interest rates.

6. Accrued Liabilities   Accrued liabilities consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 115%">Commissions</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 18%; text-align: right; line-height: 115%">563</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 18%; text-align: right; line-height: 115%">867</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Payroll and related expenses</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">359</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">683</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Royalties</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">478</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">515</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Interest payable</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">237</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">222</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Final loan payment fees</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">922</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">783</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Other</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">644</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">351</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Total accrued liabilities</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,203</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,421</td> <td style="line-height: 115%"> </td></tr> </table>

7. Debt   Hercules Term Loan   On June 30, 2014, the Company entered into a Loan and Security Agreement with Hercules which provided the Company with a $20 million term loan. The Hercules Term Loan matures on January 1, 2018. The Hercules Term Loan included a $200,000 closing fee, which was paid to Hercules on the closing date of the loan. The closing fee was recorded as a debt discount and is being amortized to interest expense over the life of the loan. The Hercules Term Loan also includes a non-refundable final payment fee of $1.7 million. The final payment fee is being accrued and recorded to interest expense over the life of the loan. The Hercules Term Loan bears interest at the rate of the greater of either (i) the prime rate plus 9.2%, and (ii) 12.5%, and was 12.7% at March 31, 2016. Interest accrues from the closing date of the loan and interest payments are due monthly. Principal payments commenced August 1, 2015 and are to be made in 30 equal installments of approximately $700,000, with the remainder due at maturity. The Companys obligations to Hercules are secured by a first priority security interest in substantially all of its assets, including intellectual property. The Hercules Term Loan contains certain covenants related to restrictions on payments to certain Company affiliates and financial reporting requirements.   On September 8, 2015, the Company entered into a Consent and First Amendment to Loan and Security Agreement (the Amendment) with Hercules. The Amendment modified the liquidity covenant to reduce the minimum cash balance required by $500,000 for every $1.0 million paid in principal to a minimum of $2.5 million. The minimum cash and cash equivalents balance required to maintain compliance with the minimum liquidity covenant at March 31, 2016 was $7.0 million. Although the Company was in compliance with the liquidity covenant at March 31, 2016, the Company anticipates that it will be non-compliant with the liquidity covenant early in the third quarter of 2016 if additional financing is not obtained or the loan is not restructured, and has therefore classified the entire obligation as a current liability.   See Note 11. Subsequent Events for further discussion with respect to the assignment of $3.0 million of the principal balance of the Hercules Term Loan to Riverside Merchant Partners, LLC (Riverside) and the subsequent agreement between the Company and Riverside to exchange the $3.0 million of the Hercules Term Loan held by Riverside for subordinated convertible promissory notes in the aggregate principal amount of $3.0 million.   Magna Note   In August 2014, the Company entered into a Securities Purchase Agreement with Magna pursuant to which the Company sold to Magna an unsecured promissory note with an aggregate principal amount of $3.5 million (the Magna Note). The outstanding principal amount of the Magna Note was $763,000 at March 31, 2016. The Magna Note matures on August 11, 2016, and accrues interest at an annual rate of 6.0%.   Outstanding long-term debt consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Outstanding Principal</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Unamortized Discount and Debt Issuance Costs</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Net Carrying Amount</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Outstanding Principal</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Unamortized Discount and Debt Issuance Costs</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Net Carrying Amount</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 34%; line-height: 115%">Hercules Term Loan</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">15,218</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">(1,186)</td> <td style="width: 1%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">14,032</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">17,051</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">(1,420)</td> <td style="width: 1%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">15,631</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Magna Note</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">763</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(10)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">753</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">763</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(29)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">734</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Total debt</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">15,981</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(1,196)</td> <td> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">14,785</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">17,814</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(1,449)</td> <td> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">16,365</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Less: Current portion</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(15,981)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">1,196</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(14,785)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(17,814)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">1,449</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(16,365)</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Long-term debt</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> </table>   The following summarizes by year the future principal payments as of March 31, 2016 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%">Years Ending December 31,</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Hercules Term Loan</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Magna Note</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; line-height: 115%">2016</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 15%; text-align: right; line-height: 115%">5,787</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 15%; text-align: right; line-height: 115%">763</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 15%; text-align: right; line-height: 115%">6,550</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">8,643</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">8,643</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">2018</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">788</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">788</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total future principal payments</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">15,218</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">763</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">15,981</td> <td style="line-height: 115%"> </td></tr> </table>

8. Equity   536,388 shares of common stock were issued upon the cashless exercise of 1,137,365 Series A warrants issued in September 2015. The remaining number of Series A warrants was 100,000 at March 31, 2016.

9. Stock-Based Compensation   Option and Equity Plans   In January 2016, the aggregate number of shares issuable under the 2012 Employee, Director and Consultant Equity Incentive Plan (the 2012 Plan) was increased by 37,879 to 342,425, in accordance with the 2012 plan.   The total number of shares available for grant under the 2012 Plan at March 31, 2016 was 121,248.   Stock Options   A summary of the Companys stock option activity for the three months ended March 31, 2016 was as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Options</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted-Average Exercise Price</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 115%">Outstanding at December 31, 2015</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 18%; text-align: right; line-height: 115%">112,373</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 18%; text-align: right; line-height: 115%">41.53</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">23,004</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.69</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Expired</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">13,702</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">24.17</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Outstanding at March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">121,675</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">35.95</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercisable at March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">74,859</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">60.65</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Vested and expected to vest at March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">119,112</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">36.50</td> <td style="line-height: 115%"> </td></tr> </table>   The Company estimates the fair value of each stock option on the grant date using the Black-Scholes-Merton valuation model, which requires several estimates including an estimate of the fair value of the underlying common stock on grant date. The expected volatility was based on an average of the historical volatility of a peer group of similar companies. The expected term was calculated utilizing the simplified method. The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the option. The following weighted average assumptions were used in the calculation to estimate the fair value of options granted to employees during the three months ended March 31, 2016 and 2015:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Three Months Ended March 31,</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%; line-height: 115%">Weighted-average risk-free interest rate</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">1.86%</td> <td style="width: 1%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">1.62%</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Weighted-average expected life (in years)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6.3</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6.3</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expected dividend yield</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0%</td> <td> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0%</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Weighted-average expected volatility</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">65%</td> <td> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">46%</td> <td style="line-height: 115%"> </td></tr> </table>   Summary of Stock-Based Compensation Expense   Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss was allocated as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Three Months Ended March 31,</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%; line-height: 115%">Cost of revenue</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 15%; text-align: right; line-height: 115%">4</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 15%; text-align: right; line-height: 115%">29</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Research and development</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">29</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">122</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">General and administrative</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">40</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">328</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Selling and marketing</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">15</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">142</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Capitalized into inventory</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">2</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">39</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total stock-based compensation expense</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">90</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">660</td> <td style="line-height: 115%"> </td></tr> </table>   Unrecognized stock-based compensation at March 31, 2016 was as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Unrecognized Stock-Based Compensation</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Remaining Period of Recognition (in years)</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%; line-height: 115%">Stock options</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 15%; text-align: right; line-height: 115%">435</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">1.7</td> <td style="width: 1%; line-height: 115%"> </td></tr> </table>

11. Subsequent Events   Hercules and Riverside Debt Assignment   On April 4, 2016, the Company entered into an Assignment and Second Amendment to Loan and Security Agreement (the Assignment Agreement) with Riverside Merchant Partners, LLC (Riverside), and Hercules, pursuant to which Hercules sold $1.0 million of the principal amount outstanding under the Hercules Term Loan, as amended to Riverside. In addition, pursuant to the terms of the Assignment Agreement, Riverside acquired an option to purchase an additional $2.0 million of the principal amount outstanding under the Hercules Term Loan from Hercules. On April 18, 2016, Riverside purchased an additional $1.0 million of the principal amount of the Hercules Term Loan and on April 27, 2016, Riverside purchased an additional $1.0 million of the principal amount of the Hercules Term Loan from Hercules.   Riverside Debt Exchange   On April 4, 2016, the Company entered into an exchange agreement (the Exchange Agreement) with Riverside, pursuant to which the Company agreed to exchange $1.0 million of the principal amount outstanding under the Hercules Term Loan held by Riverside for a subordinated convertible promissory note in the principal amount of $1.0 million (the First Exchange Note) and a warrant to purchase 100,000 shares of common stock of the Company at a fixed exercise price of $1.62 per share (the First Exchange Warrant) (the Exchange). In addition, pursuant to the terms and conditions of the Exchange Agreement, the Company and Riverside had the option to exchange an additional $2.0 million of the principal amount of the Hercules Term Loan for an additional subordinated convertible promissory note in the principal amount of up to $2.0 million and an additional warrant to purchase 100,000 shares of common stock (the Second Exchange Warrant). On April 18, 2016, the Company and Riverside exercised their option to exchange an additional $1.0 million of the principal amount of the Hercules Term Loan for an additional subordinated convertible promissory note in the principal amount of $1.0 million (the Second Exchange Note). Additionally, on April 27, 2016, the Company and Riverside exercised their option to exchange an additional $1.0 million of the principal amount of the Term Loan for an additional subordinated convertible promissory note in the principal amount of $1.0 million (the Third Exchange Note) and an additional warrant to purchase 100,000 shares of the Companys common stock at a fixed exercise price of $1.66 per share. The First Exchange Note, the Second Exchange Note and the Third Exchange Note are collectively referred to herein as the Exchange Notes.   All principal accrued under the Exchange Notes is convertible into shares of common stock at the election of the Holder at any time at a fixed conversion price of $1.43 per share (the Conversion Price). All principal outstanding under each of the Exchange Notes will be due on April 3, 2018 (the Maturity Date). Each of the Exchange Notes bears interest at a rate of 6% per annum, with the interest that would accrue on the initial principal amount of the Exchange Notes during the first 12 months being guaranteed and deemed earned as of the date of issuance. Prior to the Maturity Date, all interest accrued under the Exchange Notes is payable in cash or, if certain conditions are met, payable in shares of common stock at the Companys option, at a conversion price of $1.34 per share.   Pursuant to the terms of the Third Exchange Note, since the volume-weighted average price of the Companys common stock was less than the Conversion Price on May 6, 2016, the Company issued an additional 140,000 shares of common stock (the True-Up Shares) to Riverside.   As of May 13, 2016, the entire principal amount of the First and Second Exchange Notes, $200,000 of the Third Exchange Note, and the interest related to the First, Second, and Third Exchange Notes has been converted into 1,672,788 shares of common stock leaving the total principal balance outstanding under the Exchange Notes at $800,000.

The assumptions used in estimating the common stock warrant liability at March 31, 2016 and December 31, 2015 were as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31,2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 115%">Weighted-average risk free interest rate</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 18%; text-align: right; line-height: 115%">1.06%</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 18%; text-align: right; line-height: 115%">1.71%</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Weighted-average expected life (in years)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.55</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.7</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expected dividend yield</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0%</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Weighted average expected volatility</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">137%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">119%</td> <td style="line-height: 115%"> </td></tr> </table>

Accrued liabilities consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 115%">Commissions</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 18%; text-align: right; line-height: 115%">563</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 18%; text-align: right; line-height: 115%">867</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Payroll and related expenses</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">359</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">683</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Royalties</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">478</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">515</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Interest payable</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">237</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">222</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Final loan payment fees</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">922</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">783</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Other</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">644</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">351</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Total accrued liabilities</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,203</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,421</td> <td style="line-height: 115%"> </td></tr> </table>

Outstanding long-term debt consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Outstanding Principal</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Unamortized Discount and Debt Issuance Costs</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Net Carrying Amount</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Outstanding Principal</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Unamortized Discount and Debt Issuance Costs</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Net Carrying Amount</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 34%; line-height: 115%">Hercules Term Loan</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">15,218</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">(1,186)</td> <td style="width: 1%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">14,032</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">17,051</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">(1,420)</td> <td style="width: 1%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">15,631</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Magna Note</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">763</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(10)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">753</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">763</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(29)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">734</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Total debt</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">15,981</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(1,196)</td> <td> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">14,785</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">17,814</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(1,449)</td> <td> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">16,365</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Less: Current portion</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(15,981)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">1,196</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(14,785)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(17,814)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">1,449</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(16,365)</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Long-term debt</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> </table>

The following summarizes by year the future principal payments as of March 31, 2016 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%">Years Ending December 31,</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Hercules Term Loan</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Magna Note</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; line-height: 115%">2016</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 15%; text-align: right; line-height: 115%">5,787</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 15%; text-align: right; line-height: 115%">763</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 15%; text-align: right; line-height: 115%">6,550</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">8,643</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">8,643</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">2018</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">788</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">788</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total future principal payments</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">15,218</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">763</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">15,981</td> <td style="line-height: 115%"> </td></tr> </table>

A summary of the Companys stock option activity for the three months ended March 31, 2016 was as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Options</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted-Average Exercise Price</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 115%">Outstanding at December 31, 2015</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 18%; text-align: right; line-height: 115%">112,373</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 18%; text-align: right; line-height: 115%">41.53</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">23,004</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.69</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Expired</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">13,702</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">24.17</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Outstanding at March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">121,675</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">35.95</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercisable at March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">74,859</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">60.65</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Vested and expected to vest at March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">119,112</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">36.50</td> <td style="line-height: 115%"> </td></tr> </table>

The following weighted average assumptions were used in the calculation to estimate the fair value of options granted to employees during the three months ended March 31, 2016 and 2015:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Three Months Ended March 31,</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%; line-height: 115%">Weighted-average risk-free interest rate</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">1.86%</td> <td style="width: 1%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">1.62%</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Weighted-average expected life (in years)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6.3</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6.3</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expected dividend yield</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0%</td> <td> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0%</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Weighted-average expected volatility</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">65%</td> <td> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">46%</td> <td style="line-height: 115%"> </td></tr> </table>

Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss was allocated as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Three Months Ended March 31,</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%; line-height: 115%">Cost of revenue</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 15%; text-align: right; line-height: 115%">4</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 15%; text-align: right; line-height: 115%">29</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Research and development</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">29</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">122</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">General and administrative</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">40</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">328</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Selling and marketing</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">15</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">142</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Capitalized into inventory</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">2</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">39</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total stock-based compensation expense</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">90</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">660</td> <td style="line-height: 115%"> </td></tr> </table>

Unrecognized stock-based compensation at March 31, 2016 was as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Unrecognized Stock-Based Compensation</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Remaining Period of Recognition (in years)</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%; line-height: 115%">Stock options</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 15%; text-align: right; line-height: 115%">435</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">1.7</td> <td style="width: 1%; line-height: 115%"> </td></tr> </table>

121248

342425

8492000

9131000

11422636

10886248

11422636

10886248

-7000

3000

3000000

1000000

2000000

1000000

2900000

800000

788000

819000

229000

235000

7475000

8077000

-6000

Principal payments commenced August 1, 2015 and are to be made in 30 equal installments of approximately $700,000, with the remainder due at maturity.

37879

2500000

The Amendment modified the liquidity covenant to reduce the minimum cash balance required by $500,000 for every $1.0 million paid in principal to a minimum of $2.5 million. The minimum cash and cash equivalents balance required to maintain compliance with the minimum liquidity covenant at March 31, 2016 was $7.0 million.

1.62

1.66

1.34

1.43

P12M

0001269026

-13702

24.17

2. Basic and Diluted Net Loss per Common Share   Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of warrants for the purchase of common stock, convertible notes, stock options and unvested restricted stock units. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding because their effect would have been anti-dilutive due to the Company reporting a net loss. The Company had potentially dilutive securities representing approximately 800,000 and 2.9 million shares of common stock at March 31, 2016 and 2015, respectively.

10. Commitments and Contingencies   On April 1, 2016, Hampshire MedTech Partners II, GP (Hampshire GP) filed suit against the Company in the Travis County, Texas 200th Judicial District Court relating to a Warrant to Purchase Shares of Common Stock issued to Hampshire MedTech Partners II, LP (Hampshire LP) on November 6, 2014 (the Warrant). Hampshire GP alleges that as a result of a subsequent financing the Company breached the anti-dilution provision of the Warrant by failing to increase the number of shares subject to the Warrant as well as failing to reduce the exercise price of the Warrant. Hampshire GP seeks damages in excess of $1,000,000. The Company has not yet answered Hampshire GPs complaint and intends to vigorously defend itself in this suit.   From time to time, the Company is subject to other various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. Management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Companys consolidated financial position, operating results or cash flows.

The following is a reconciliation of the effect of these reclassifications on the Companys Condensed Consolidated Balance Sheet at December 31, 2015 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">As Reported</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Adjustments</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">As Revised</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Assets:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 58%; padding-left: 10pt; line-height: 115%">Prepaid expenses and other current assets</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">821</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(592)</td> <td style="width: 1%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">229</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Liabilities:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Current portion of long-term debt</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">16,957</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(592)</td> <td> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">16,365</td> <td style="line-height: 115%"> </td></tr> </table>

The components of inventory were as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 115%">Raw materials</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">788</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">819</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">WIP</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">229</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">235</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Finished Goods</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">7,475</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">8,077</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total inventory</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">8,492</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">9,131</td> <td style="line-height: 115%"> </td></tr> </table>

Intangible assets consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 115%">Customer relationships</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 18%; text-align: right; line-height: 115%">3,990</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 18%; text-align: right; line-height: 115%">3,990</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Developed technology</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,685</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,685</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Other patents and patent applications</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">562</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">562</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Trademarks</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">350</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">350</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Total intangibles</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">9,587</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">9,587</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Less accumulated amortization</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(6,025)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(5,900)</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Total intangibles net of amortization</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,562</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,687</td> <td style="line-height: 115%"> </td></tr> </table>

The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy at March 31, 2016 and December 31, 2015:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Fair Value Measurements at March 31, 2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%">Description</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 1</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Derivative liability</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-left: 10pt; line-height: 115%">Common stock warrants</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">604</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">604</td> <td style="width: 1%; line-height: 115%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Fair Value Measurements at December 31, 2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%">Description</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 1</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Derivative liability</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-left: 10pt; line-height: 115%">Common stock warrants</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">598</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">598</td> <td style="width: 1%; line-height: 115%"> </td></tr> </table>

The following table presents a reconciliation of the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2016 and 2015:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Common Stock Warrants</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Preferred Stock Warrants</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Conversion Feature of Notes</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total Derivative Liability</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%; line-height: 115%">Balance at December 31, 2014</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">(11,358)</td> <td style="width: 1%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">(2,612)</td> <td style="width: 1%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">(13,970)</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Decrease in liability due to debt conversions</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">179</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">179</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; text-align: justify; line-height: 115%">Decrease in liability due to warrants being exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">723</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">723</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Change in fair value</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">435</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(612)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(177)</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Balance at March 31, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(10,200)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(3,045)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(13,245)</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Balance at December 31, 2015</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(598)</td> <td> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(598)</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; text-align: justify; line-height: 115%">Increase in fair value included in earnings, as other income</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(6)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(6)</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Balance at March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(604)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(604)</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

AMDA Q1 2016 Organization   Amedica Corporation (Amedica or the Company) was incorporated in the state of Delaware on December 10, 1996. Amedica is a commercial-stage biomaterials company focused on using its silicon nitride technology platform to develop, manufacture, and commercialize a broad range of medical devices. The Company believes it is the first and only manufacturer to use silicon nitride in medical applications. The Company acquired US Spine, Inc. (US Spine), a Delaware spinal products corporation with operations in Florida, on September 20, 2010. The Companys products are sold primarily in the United States.

Basis of Presentation   These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (SEC). Such rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Companys Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 23, 2016. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016. The Companys significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2015.   In accordance with the adoption of Accounting Standards Update (ASU) 2015-03, the Companys debt issuance costs have been reclassified to be presented in the Condensed Consolidated Balance Sheets as a direct reduction from the debt liability rather than as an asset.   The following is a reconciliation of the effect of these reclassifications on the Companys Condensed Consolidated Balance Sheet at December 31, 2015 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">As Reported</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Adjustments</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">As Revised</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Assets:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 58%; padding-left: 10pt; line-height: 115%">Prepaid expenses and other current assets</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">821</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(592)</td> <td style="width: 1%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">229</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Liabilities:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Current portion of long-term debt</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">16,957</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(592)</td> <td> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">16,365</td> <td style="line-height: 115%"> </td></tr> </table>

Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Some of the more significant estimates relate to inventory, stock-based compensation, long-lived and intangible assets and the liability for preferred stock and common stock warrants.

Liquidity and Capital Resources   For the three months ended March 31, 2016 and 2015, the Company incurred a net loss of $3.4 million and $5.4 million, respectively, and used cash in operations of $1.5 million and $3 million, respectively. The Company had an accumulated deficit of $199.9 million and $196.5 million at March 31, 2016 and December 31, 2015, respectively. To date, the Companys operations have been principally financed from proceeds from the issuance of preferred and common stock, convertible debt and bank debt and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations through 2016.   As discussed further in Note 7, the Company has entered into a term loan with Hercules Technology Growth Capital, Inc. (Hercules Technology), as administrative and collateral agent for the lenders thereunder and as lender, and Hercules Technology III, LP, (HT III and, together with Hercules Technology, Hercules) as lender (the Hercules Term Loan). The Hercules Term Loan has a liquidity covenant that requires the Company to maintain a cash balance of not less than $7.0 million at March 31, 2016. At March 31, 2016, the Companys cash balance was approximately $7.9 million. The Company anticipates that it will need to refinance the note or obtain additional funding early in the third quarter of 2016 to maintain compliance through 2016 with the liquidity covenant related to the Hercules Term Loan. However, if the Company is unable to refinance the note or access additional funds prior to becoming non-compliant with the financial and liquidity covenants related to the Hercules Term Loan, the entire remaining balance of the debt under the Hercules Term Loan could become immediately due and payable at the option of the lender. Although the Company is seeking to refinance the note or obtain additional financing, additional funding may not be available to the Company on favorable or acceptable terms, or at all. Any additional equity financing, if available to the Company, will most likely be dilutive to its current stockholders, and debt financing, if available, may involve more restrictive covenants. The Companys ability to access capital when needed is not assured and, if not achieved on a timely basis, will materially harm its business, financial condition and results of operations. These uncertainties create substantial doubt about the Companys ability to continue as a going concern. No adjustment has been made to our financial statements as a result of this uncertainty.   See Note 11. Subsequent Events for further discussion with respect to the assignment of $3.0 million of the principal balance of the Hercules Term Loan to Riverside Merchant Partners, LLC (Riverside) and the subsequent agreement between the Company and Riverside to exchange the $3.0 million of the Hercules Term Loan held by Riverside for subordinated convertible promissory notes in the aggregate principal amount of $3.0 million.

New Accounting Pronouncements   In March 2016 the Financial Accounting Standards Board (FASB) updated the accounting guidance related to stock compensation. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company is still evaluating the impact that this standard will have on its consolidated financial statements.   In February 2016, the FASB updated the accounting guidance related to leases as part of a joint project with the International Accounting Standards Board (IASB) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, a lessee will be required to recognize assets and liabilities for capital and operating leases with lease terms of more than 12 months. Additionally, this ASU will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases, including qualitative and quantitative requirements. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the potential impact this new standard may have on its financial statements.   In August 2014, the FASB updated the accounting guidance related to disclosure of uncertainties about an entitys ability to continue as a going concern. The new standard provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. It requires management to perform interim and annual assessments of an entitys ability to continue as a going concern. The new standard is effective for annual periods ending after December 15, 2016, and interim periods thereafter. Early adoption is permitted. The impact on the Companys financial statements of adopting the new standard is currently being assessed by management.   In May 2014, the FASB updated the accounting guidance related to revenue from contracts with customers, which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle is that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The standard defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, and shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is evaluating the potential impact of this adoption on its consolidated financial statements.

1137365

1000000

EX-101.SCH 6 amda-20160331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basic and Diluted Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Organization and Summary of Significant Accounting Policies - Schedule of Reconciliation of Effect of Reclassifications on Condensed Consolidated Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Basic and Diluted Net Loss Per Common Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Inventories (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Inventories - Components of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Fair Value Measurements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Fair Value Measurements - Schedule of Reconciliation of Derivative Liability Measured on Recurring Basis Using Unobservable Inputs (Level 3) (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Fair Value Measurements - Schedule of Assumptions used in Estimating Common Stock Warrant Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Debt - Schedule of Outstanding Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Debt - Schedule of Future Principal Payments on Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Stock-Based Compensation - Schedule of Black-Scholes-Merton Option Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Stock-Based Compensation - Schedule of Unrecognized Compensation Cost, Nonvested Awards (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 amda-20160331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 amda-20160331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 amda-20160331_lab.xml XBRL LABEL FILE Convertible Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-In Capital (Capital Deficiency) [Member] Accumulated Deficit [Member] Convertible Notes Payable [Member] Short-term Debt, Type [Axis] Employee Stock Option [Member] Award Type [Axis] January 25, 2016 Report Date [Axis] Accounts Receivable [Member] Concentration Risk Benchmark [Axis] One Customer [Member] Concentration Risk Type [Axis] No Customer [Member] Revenue [Member] Two Customer [Member] Common Stock Warrants [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Common Stock Options [Member] Restricted Stock Units [Member] Manufacturing And Lab Equipment [Member] Property Plant And Equipment By Type [Axis] Surgical Instruments [Member] Leasehold Improvements [Member] Software And Computer Equipment [Member] Furniture And Fixtures [Member] Customer Relationships [Member] Finite Lived Intangible Assets By Major Class [Axis] Developed Technology [Member] Other Patents And Patent Applications [Member] Trademarks [Member] Indefinite Lived Intangible Assets By Major Class [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Recurring [Member] Measurement Frequency [Axis] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Conversion Feature Of Notes [Member] Derivative Financial Instruments, Liabilities [Member] Liability Class [Axis] Preferred Stock Warrants[Member] Hercules Term Loan [Member] Debt Instrument [Axis] Magna Note [Member] Magna Additional Convertible Notes [Member] Magna Convertible Notes [Member] Magna Note [Member] Hercules Technology Capital, Inc. [Member] Related Party Transactions By Related Party [Axis] Loan and Security Agreement [Member] Agreement [Axis] Initial Convertible Note [Member] Additional Convertible Note [Member] Prime Rate [Member] Variable Rate [Axis] First Amendment to Loan and Security Agreement [Member] September 8, 2016 And Thereafter [Member] Minimum [Member] Range [Axis] Maximum [Member] Amendment Agreement [Member] September 2015 [Member] June Note [Member] August Note [Member] Magna August Note [Member] 2012 Plan [Member] Plan Name [Axis] Restricted stock awards [Member] Stock-Based Awards Granted To Nonemployees [Member] Restricted Stock Units (RSUs) [Member] Cost Of Revenue [Member] Income Statement Location [Axis] Research and Development [Member] General and Administrative [Member] Selling and Marketing [Member] Capitalized Into Inventory [Member] Operating Leases [Member] Income Tax Authority [Axis] Sublease Income [Member] Consulting Agreement [Member] Related Party Transaction [Axis] Creation Capital Advisors [Member] Contract Termination [Member] Subsequent Event [Member] Subsequent Event Type [Axis] Assignment Agreement [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Riverside Merchant Partners, LLC [Member] September 2015 Offering [Member] Sale of Stock [Axis] Series A Warrants [Member] Series B Warrants [Member] Investors [Member] Series C Warrants [Member] Placement Agent [Member] November 2014 Secondary Offering [Member] IPO [Member] Underwriters [Member] Series F Convertible Preferred Stock [Member] Other Issuances [Member] Other Warrants [Member] Over-Allotment Option [Member] Underwriter [Member] Warrants [Member] Stock Options to Non-employees [Member] Previously Reported [Member] Scenario [Axis] Adjustment [Member] Securities Purchase Agreement [Member] Exchange Agreement [Member] Third Exchange Note [Member] First Exchange Note [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets: Cash and cash equivalents Trade accounts receivable, net of allowance of $28 and $49, respectively Prepaid expenses and other current assets Inventories, net Total current assets Property and equipment, net Intangible assets, net Goodwill Other long-term assets Total assets Liabilities and stockholders’ equity Current liabilities: Accounts payable Accrued liabilities Current portion of long-term debt Total current liabilities Deferred rent Other long-term liabilities Derivative liabilities Commitments and contingencies Stockholders’ equity: Common stock, $0.01 par value; 250,000,000 shares authorized; 11,422,636 and 10,886,248 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively Additional paid-in capital Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Allowance of trade accounts receivable Common stock, per share Common stock, authorized, shares Common stock, issued, shares Common stock, outstanding, shares Income Statement [Abstract] Product revenue Costs of revenue Gross profit Operating expenses: Research and development General and administrative Sales and marketing Total operating expenses Loss from operations Other income (expense): Interest expense Loss on extinguishment of debt Change in fair value of derivative liabilities Loss on extinguishment of derivative liabilities Other expense Total other income (expense) Net loss before income taxes Provision for income taxes Total comprehensive loss Net loss per share attributable to common stockholders: Basic and diluted Weighted average common shares outstanding: Basic and diluted Statement of Cash Flows [Abstract] Cash flow from operating activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Amortization of intangible assets Amortization of lease incentive for tenant improvements EX-101.PRE 10 amda-20160331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	May. 13, 2016
Document And Entity Information
Entity Registrant Name	AMEDICA Corp
Entity Central Index Key	0001269026
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		13,236,071
Trading Symbol	AMDA
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2016

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 7,943	$ 11,485
Trade accounts receivable, net of allowance of $28 and $49, respectively	1,848	2,660
Prepaid expenses and other current assets	705	229
Inventories, net	8,492	9,131
Total current assets	18,988	23,505
Property and equipment, net	2,333	2,472
Intangible assets, net	3,562	3,687
Goodwill	6,163	6,163
Other long-term assets	35	35
Total assets	31,081	35,862
Current liabilities:
Accounts payable	982	643
Accrued liabilities	3,203	3,421
Current portion of long-term debt	14,785	16,365
Total current liabilities	18,970	20,429
Deferred rent	405	432
Other long-term liabilities	169	171
Derivative liabilities	604	598
Stockholders’ equity:
Common stock, $0.01 par value; 250,000,000 shares authorized; 11,422,636 and 10,886,248 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively	114	109
Additional paid-in capital	210,744	210,660
Accumulated deficit	(199,925)	(196,537)
Total stockholders’ equity	10,933	14,232
Total liabilities and stockholders’ equity	$ 31,081	$ 35,862

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Allowance of trade accounts receivable	$ 28	$ 49
Common stock, per share	$ 0.01	$ 0.01
Common stock, authorized, shares	250,000,000	250,000,000
Common stock, issued, shares	11,422,636	10,886,248
Common stock, outstanding, shares	11,422,636	10,886,248

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Product revenue	$ 4,173	$ 4,743
Costs of revenue	893	1,522
Gross profit	3,280	3,221
Operating expenses:
Research and development	1,608	1,843
General and administrative	1,562	2,027
Sales and marketing	2,594	3,357
Total operating expenses	5,764	7,227
Loss from operations	(2,484)	(4,006)
Other income (expense):
Interest expense	$ (900)	(1,100)
Loss on extinguishment of debt		(79)
Change in fair value of derivative liabilities	$ (11)	(177)
Loss on extinguishment of derivative liabilities		(16)
Other expense	$ 7	(3)
Total other income (expense)	(904)	(1,375)
Net loss before income taxes	$ (3,388)	$ (5,381)
Provision for income taxes
Total comprehensive loss	$ (3,388)	$ (5,381)
Net loss per share attributable to common stockholders:
Basic and diluted	$ (0.30)	$ (3.00)
Weighted average common shares outstanding:
Basic and diluted	11,193,250	1,795,296

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flow from operating activities
Net loss	$ (3,388)	$ (5,381)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	389	428
Amortization of intangible assets	125	125
Amortization of lease incentive for tenant improvements	5	5
Non cash interest expense	$ 405	551
Loss on extinguishment of debt		79
Stock based compensation	$ 88	592
Change in fair value of derivative liabilities	$ 11	177
Loss on extinguishment of derivative liabilities		16
(Gain) loss on disposal of equipment	$ (4)	3
Provision for inventory reserve	$ 373	326
Bad debt recovery		(20)
Changes in operating assets and liabilities:
Trade accounts receivable	$ 813	(35)
Prepaid expenses and other current assets	(476)	(330)
Inventories	263	293
Accounts payable and accrued liabilities	(64)	200
Net cash used in operating activities	(1,465)	(2,971)
Cash flows from investing activities
Purchase of property and equipment	(259)	(277)
Proceeds from sale of property and equipment	16	3
Net cash used in investing activities	(243)	$ (274)
Cash flows from financing activities
Payments on long-term debt	$ (1,834)
Purchase of treasury stock		$ (120)
Net cash used in financing activities	$ (1,834)	(120)
Net decrease in cash and cash equivalents	(3,542)	(3,365)
Cash and cash equivalents at beginning of period	11,485	18,247
Cash and cash equivalents at end of period	$ 7,943	14,882
Noncash investing and financing activities
Debt converted to common stock		202
Common stock issued for cashless exercise of warrant derivative liabilities		739
Supplemental cash flow information
Cash paid for interest	$ 507	$ 548

XML 16 R6.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Organization and Summary of Significant Accounting Policies

1. Organization and Summary of Significant Accounting Policies

Organization

Basis of Presentation

The following is a reconciliation of the effect of these reclassifications on the Company’s Condensed Consolidated Balance Sheet at December 31, 2015 (in thousands):

	December 31, 2015
	As Reported		Adjustments		As Revised
Assets:
Prepaid expenses and other current assets	$	821	$	(592)	$	229
Liabilities:
Current portion of long-term debt		16,957		(592)		16,365

Use of Estimates

Liquidity and Capital Resources

Significant Accounting Policies

There have been no significant changes to the Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

New Accounting Pronouncements

XML 17 R7.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Loss Per Common Share

3 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Basic and Diluted Net Loss Per Common Share

2. Basic and Diluted Net Loss per Common Share

XML 18 R8.htm IDEA: XBRL DOCUMENT

Inventories

3 Months Ended

Mar. 31, 2016

Inventory Disclosure [Abstract]

Inventories

3. Inventories

The components of inventory were as follows (in thousands):

	March 31, 2016		December 31, 2015
Raw materials	$	788	$	819
WIP		229		235
Finished Goods		7,475		8,077
Total inventory	$	8,492	$	9,131

Finished goods include consigned inventory in the amounts of approximately $3.4 million and $3.8 million as of March 31, 2016 and December 31, 2015, respectively.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Intangible Assets

3 Months Ended

Mar. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

4. Intangible Assets

Intangible assets consisted of the following (in thousands):

	March 31, 2016		December 31, 2015
Customer relationships	$	3,990	$	3,990
Developed technology		4,685		4,685
Other patents and patent applications		562		562
Trademarks		350		350
Total intangibles		9,587		9,587
Less accumulated amortization		(6,025)		(5,900)
Total intangibles net of amortization	$	3,562	$	3,687

XML 20 R10.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2016

Fair Value Measurements And Marketable Securities [Abstract]

Fair Value Measurements

5. Fair Value Measurements

Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis

Level 1	-	quoted market prices for identical assets or liabilities in active markets.

Level 2	-	observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

Level 3	-	unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

	Fair Value Measurements at March 31, 2016
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	604	$	604

	Fair Value Measurements at December 31, 2015
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	598	$	598

	Common Stock Warrants		Preferred Stock Warrants		Conversion Feature of Notes		Total Derivative Liability
Balance at December 31, 2014	$	(11,358)	$	-	$	(2,612)	$	(13,970)
Decrease in liability due to debt conversions		-		-		179		179
Decrease in liability due to warrants being exercised		723		-		-		723
Change in fair value		435		-		(612)		(177)
Balance at March 31, 2015	$	(10,200)	$	-	$	(3,045)	$	(13,245)

Balance at December 31, 2015	$	(598)	$	-	$	-	$	(598)
Increase in fair value included in earnings, as other income		(6)		-		-		(6)
Balance at March 31, 2016	$	(604)	$	-	$	-	$	(604)

Common Stock Warrants

The assumptions used in estimating the common stock warrant liability at March 31, 2016 and December 31, 2015 were as follows:

	March 31,2016		December 31, 2015
Weighted-average risk free interest rate		1.06%		1.71%
Weighted-average expected life (in years)		3.55		3.7
Expected dividend yield		0%		0%
Weighted average expected volatility		137%		119%

Other Financial Instruments

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

3 Months Ended

Mar. 31, 2016

Payables and Accruals [Abstract]

Accrued Liabilities

6. Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	March 31, 2016		December 31, 2015
Commissions	$	563	$	867
Payroll and related expenses		359		683
Royalties		478		515
Interest payable		237		222
Final loan payment fees		922		783
Other		644		351
Total accrued liabilities	$	3,203	$	3,421

XML 22 R12.htm IDEA: XBRL DOCUMENT

Debt

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Debt

7. Debt

Hercules Term Loan

Magna Note

Outstanding long-term debt consisted of the following (in thousands):

	March 31, 2016						December 31, 2015
	Outstanding Principal		Unamortized Discount and Debt Issuance Costs		Net Carrying Amount		Outstanding Principal		Unamortized Discount and Debt Issuance Costs		Net Carrying Amount
Hercules Term Loan		15,218		(1,186)		14,032		17,051		(1,420)		15,631
Magna Note		763		(10)		753		763		(29)		734
Total debt		15,981		(1,196)		14,785		17,814		(1,449)		16,365
Less: Current portion		(15,981)		1,196		(14,785)		(17,814)		1,449		(16,365)
Long-term debt	$	-	$	-	$	-	$	-	$	-	$	-

The following summarizes by year the future principal payments as of March 31, 2016 (in thousands):

Years Ending December 31,	Hercules Term Loan		Magna Note		Total
2016	$	5,787	$	763	$	6,550
2017		8,643		-		8,643
2018		788		-		788
Total future principal payments	$	15,218	$	763	$	15,981

XML 23 R13.htm IDEA: XBRL DOCUMENT

Equity

3 Months Ended

Mar. 31, 2016

Equity [Abstract]

Equity

8. Equity

536,388 shares of common stock were issued upon the cashless exercise of 1,137,365 Series A warrants issued in September 2015. The remaining number of Series A warrants was 100,000 at March 31, 2016.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

3 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

9. Stock-Based Compensation

Option and Equity Plans

The total number of shares available for grant under the 2012 Plan at March 31, 2016 was 121,248.

Stock Options

A summary of the Company’s stock option activity for the three months ended March 31, 2016 was as follows:

	Options		Weighted-Average Exercise Price
Outstanding at December 31, 2015		112,373	$	41.53
Granted		23,004	$	1.69
Expired		13,702	$	24.17
Outstanding at March 31, 2016		121,675	$	35.95
Exercisable at March 31, 2016		74,859	$	60.65
Vested and expected to vest at March 31, 2016		119,112	$	36.50

	Three Months Ended March 31,
	2016		2015
Weighted-average risk-free interest rate		1.86%		1.62%
Weighted-average expected life (in years)		6.3		6.3
Expected dividend yield		0%		0%
Weighted-average expected volatility		65%		46%

Summary of Stock-Based Compensation Expense

Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss was allocated as follows (in thousands):

	Three Months Ended March 31,
	2016		2015
Cost of revenue	$	4	$	29
Research and development		29		122
General and administrative		40		328
Selling and marketing		15		142
Capitalized into inventory		2		39
Total stock-based compensation expense	$	90	$	660

Unrecognized stock-based compensation at March 31, 2016 was as follows (in thousands):

		Unrecognized Stock-Based Compensation				Weighted Average Remaining Period of Recognition (in years)
Stock options		$	435				1.7

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10. Commitments and Contingencies

XML 26 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Mar. 31, 2016

Subsequent Events [Abstract]

Subsequent Events

11. Subsequent Events

Hercules and Riverside Debt Assignment

Riverside Debt Exchange

XML 27 R17.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Organization

Organization

Basis of Presentation

Basis of Presentation

The following is a reconciliation of the effect of these reclassifications on the Company’s Condensed Consolidated Balance Sheet at December 31, 2015 (in thousands):

	December 31, 2015
	As Reported		Adjustments		As Revised
Assets:
Prepaid expenses and other current assets	$	821	$	(592)	$	229
Liabilities:
Current portion of long-term debt		16,957		(592)		16,365

Use of Estimates

Use of Estimates

Liquidity and Capital Resources

Liquidity and Capital Resources

New Accounting Pronouncements

New Accounting Pronouncements

XML 28 R18.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Schedule of Reconciliation of Effect of Reclassifications on Condensed Consolidated Balance Sheet

The following is a reconciliation of the effect of these reclassifications on the Company’s Condensed Consolidated Balance Sheet at December 31, 2015 (in thousands):

	December 31, 2015
	As Reported		Adjustments		As Revised
Assets:
Prepaid expenses and other current assets	$	821	$	(592)	$	229
Liabilities:
Current portion of long-term debt		16,957		(592)		16,365

XML 29 R19.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

3 Months Ended

Mar. 31, 2016

Inventory Disclosure [Abstract]

Components of Inventory

The components of inventory were as follows (in thousands):

	March 31, 2016		December 31, 2015
Raw materials	$	788	$	819
WIP		229		235
Finished Goods		7,475		8,077
Total inventory	$	8,492	$	9,131

XML 30 R20.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets consisted of the following (in thousands):

	March 31, 2016		December 31, 2015
Customer relationships	$	3,990	$	3,990
Developed technology		4,685		4,685
Other patents and patent applications		562		562
Trademarks		350		350
Total intangibles		9,587		9,587
Less accumulated amortization		(6,025)		(5,900)
Total intangibles net of amortization	$	3,562	$	3,687

XML 31 R21.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy

The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy at March 31, 2016 and December 31, 2015:

	Fair Value Measurements at March 31, 2016
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	604	$	604

	Fair Value Measurements at December 31, 2015
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	598	$	598

Schedule of Reconciliation of Derivative Liability Measured on Recurring Basis Using Unobservable Inputs (Level 3)

The following table presents a reconciliation of the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2016 and 2015:

	Common Stock Warrants		Preferred Stock Warrants		Conversion Feature of Notes		Total Derivative Liability
Balance at December 31, 2014	$	(11,358)	$	-	$	(2,612)	$	(13,970)
Decrease in liability due to debt conversions		-		-		179		179
Decrease in liability due to warrants being exercised		723		-		-		723
Change in fair value		435		-		(612)		(177)
Balance at March 31, 2015	$	(10,200)	$	-	$	(3,045)	$	(13,245)

Balance at December 31, 2015	$	(598)	$	-	$	-	$	(598)
Increase in fair value included in earnings, as other income		(6)		-		-		(6)
Balance at March 31, 2016	$	(604)	$	-	$	-	$	(604)

Schedule of Assumptions used in Estimating Common Stock Warrant Liability

The assumptions used in estimating the common stock warrant liability at March 31, 2016 and December 31, 2015 were as follows:

	March 31,2016		December 31, 2015
Weighted-average risk free interest rate		1.06%		1.71%
Weighted-average expected life (in years)		3.55		3.7
Expected dividend yield		0%		0%
Weighted average expected volatility		137%		119%

XML 32 R22.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2016

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	March 31, 2016		December 31, 2015
Commissions	$	563	$	867
Payroll and related expenses		359		683
Royalties		478		515
Interest payable		237		222
Final loan payment fees		922		783
Other		644		351
Total accrued liabilities	$	3,203	$	3,421

XML 33 R23.htm IDEA: XBRL DOCUMENT

Debt (Tables)

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Schedule of Outstanding Long-Term Debt

Outstanding long-term debt consisted of the following (in thousands):

	March 31, 2016						December 31, 2015
	Outstanding Principal		Unamortized Discount and Debt Issuance Costs		Net Carrying Amount		Outstanding Principal		Unamortized Discount and Debt Issuance Costs		Net Carrying Amount
Hercules Term Loan		15,218		(1,186)		14,032		17,051		(1,420)		15,631
Magna Note		763		(10)		753		763		(29)		734
Total debt		15,981		(1,196)		14,785		17,814		(1,449)		16,365
Less: Current portion		(15,981)		1,196		(14,785)		(17,814)		1,449		(16,365)
Long-term debt	$	-	$	-	$	-	$	-	$	-	$	-

Schedule of Future Principal Payments on Debt

The following summarizes by year the future principal payments as of March 31, 2016 (in thousands):

Years Ending December 31,	Hercules Term Loan		Magna Note		Total
2016	$	5,787	$	763	$	6,550
2017		8,643		-		8,643
2018		788		-		788
Total future principal payments	$	15,218	$	763	$	15,981

XML 34 R24.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Stock Option Activity

A summary of the Company’s stock option activity for the three months ended March 31, 2016 was as follows:

	Options		Weighted-Average Exercise Price
Outstanding at December 31, 2015		112,373	$	41.53
Granted		23,004	$	1.69
Expired		13,702	$	24.17
Outstanding at March 31, 2016		121,675	$	35.95
Exercisable at March 31, 2016		74,859	$	60.65
Vested and expected to vest at March 31, 2016		119,112	$	36.50

Schedule of Black-Scholes-Merton Option Pricing Model

The following weighted average assumptions were used in the calculation to estimate the fair value of options granted to employees during the three months ended March 31, 2016 and 2015:

	Three Months Ended March 31,
	2016		2015
Weighted-average risk-free interest rate		1.86%		1.62%
Weighted-average expected life (in years)		6.3		6.3
Expected dividend yield		0%		0%
Weighted-average expected volatility		65%		46%

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss was allocated as follows (in thousands):

	Three Months Ended March 31,
	2016		2015
Cost of revenue	$	4	$	29
Research and development		29		122
General and administrative		40		328
Selling and marketing		15		142
Capitalized into inventory		2		39
Total stock-based compensation expense	$	90	$	660

Schedule of Unrecognized Compensation Cost, Nonvested Awards

Unrecognized stock-based compensation at March 31, 2016 was as follows (in thousands):

		Unrecognized Stock-Based Compensation				Weighted Average Remaining Period of Recognition (in years)
Stock options		$	435				1.7

XML 35 R25.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Net loss	$ 3,388	$ 5,381
Net cash used in operating activities	1,465	2,971
Accumulated deficit	$ 199,925		$ 196,537
Debt instrument, payment terms	As discussed further in Note 7, the Company has entered into a term loan with Hercules Technology Growth Capital, Inc. (“Hercules Technology”), as administrative and collateral agent for the lenders thereunder and as lender, and Hercules Technology III, LP, (“HT III” and, together with Hercules Technology, “Hercules”) as lender (the “Hercules Term Loan”). The Hercules Term Loan has a liquidity covenant that requires the Company to maintain a cash balance of not less than $7.0 million at March 31, 2016.
Cash and cash equivalents	$ 7,943	$ 14,882	11,485	$ 18,247
Debt principal amount	15,981		17,814
Hercules Term Loan [Member]
Debt principal amount	15,218		$ 17,051
Hercules Term Loan [Member] \| Minimum [Member]
Cash and cash equivalents	7,000
Riverside Merchant Partners, LLC [Member]
Debt principal amount	3,000
Subordinated convertible promissory notes	$ 3,000

XML 36 R26.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies - Schedule of Reconciliation of Effect of Reclassifications on Condensed Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Prepaid expenses and other current assets	$ 705	$ 229
Current portion of long-term debt	$ 14,785	16,365
Previously Reported [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Prepaid expenses and other current assets		821
Current portion of long-term debt		16,957
Adjustment [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Prepaid expenses and other current assets		(592)
Current portion of long-term debt		$ (592)

XML 37 R27.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Loss Per Common Share (Details Narrative) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Common Stock [Member]
Potentially dilutive securities	800,000	2,900,000

XML 38 R28.htm IDEA: XBRL DOCUMENT

Inventories (Details Narrative) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Inventories Details Narrative
Finished goods include consigned inventory	$ 3,400	$ 3,800

XML 39 R29.htm IDEA: XBRL DOCUMENT

Inventories - Components of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 788	$ 819
WIP	229	235
Finished Goods	7,475	8,077
Total inventory	$ 8,492	$ 9,131

XML 40 R30.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details Narrative) $ in Thousands	Mar. 31, 2016 USD ($)
Intangible Assets Details Narrative
Estimated amortization expense, remainder of 2016	$ 375
Estimated amortization expense, 2017	501
Estimated amortization expense, 2018	501
Estimated amortization expense, 2019	501
Estimated amortization expense, 2020	501
Estimated amortization expense, thereafter	$ 834

XML 41 R31.htm IDEA: XBRL DOCUMENT

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Total intangibles	$ 9,587	$ 9,587
Less accumulated amortization	(6,025)	(5,900)
Total intangibles net of amortization	3,562	3,687
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangibles	350	350
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangibles	3,990	3,990
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangibles	4,685	4,685
Other Patents And Patent Applications [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangibles	$ 562	$ 562

XML 42 R32.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details Narrative) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Financial assets measured on recurring basis

XML 43 R33.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 604	$ 598
Fair Value, Measurements, Recurring [Member] \| Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 604	$ 598
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Measurements, Recurring [Member] \| Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Measurements, Recurring [Member] \| Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Measurements, Recurring [Member] \| Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 604	$ 598

XML 44 R34.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Reconciliation of Derivative Liability Measured on Recurring Basis Using Unobservable Inputs (Level 3) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in fair value	$ 11	$ 177
Derivative Financial Instruments, Liabilities [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	(598)	(13,970)
Decrease in liability due to debt conversions		179
Decrease in liability due to warrants being exercised		723
Change in fair value		(177)
Increase in fair value included in earnings, as other income	(6)
Ending balance	(604)	(13,245)
Derivative Financial Instruments, Liabilities [Member] \| Common Stock Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	(598)	$ (11,358)
Decrease in liability due to debt conversions
Decrease in liability due to warrants being exercised		$ 723
Change in fair value		435
Increase in fair value included in earnings, as other income	(6)
Ending balance	$ (604)	$ (10,200)
Derivative Financial Instruments, Liabilities [Member] \| Preferred Stock Warrants[Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance
Decrease in liability due to debt conversions
Decrease in liability due to warrants being exercised
Change in fair value
Increase in fair value included in earnings, as other income
Ending balance
Derivative Financial Instruments, Liabilities [Member] \| Conversion Feature Of Notes [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance		$ (2,612)
Decrease in liability due to debt conversions		$ 179
Decrease in liability due to warrants being exercised
Change in fair value		$ (612)
Increase in fair value included in earnings, as other income
Ending balance		$ (3,045)

XML 45 R35.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Assumptions used in Estimating Common Stock Warrant Liability (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Weighted-average risk free interest rate	1.06%	1.71%
Weighted-average expected life (in years)	3 years 6 months 18 days	3 years 8 months 12 days
Expected dividend yield	0.00%	0.00%
Weighted average expected volatility	137.00%	119.00%

XML 46 R36.htm IDEA: XBRL DOCUMENT

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Accrued Liabilities, Current [Abstract]
Commissions	$ 563	$ 867
Payroll and related expenses	359	683
Royalties	478	515
Interest payable	237	222
Final loan payment fees	922	783
Other	644	351
Total accrued liabilities	$ 3,203	$ 3,421

XML 47 R37.htm IDEA: XBRL DOCUMENT

Debt (Details Narrative) - USD ($) $ in Thousands			3 Months Ended
Debt (Details Narrative) - USD ($) $ in Thousands	Sep. 08, 2015	Jun. 30, 2014	Mar. 31, 2016	Dec. 31, 2015	Aug. 31, 2014
Debt principal amount			$ 15,981	$ 17,814
Hercules Term Loan [Member]
Debt principal amount			$ 15,218	17,051
Term loan fee amount		$ 200
Final payment fee for debt		$ 1,700
Percentage of loan bear interest rate			12.70%
Term loan, payment terms			Principal payments commenced August 1, 2015 and are to be made in 30 equal installments of approximately $700,000, with the remainder due at maturity.
Debt instrument, periodic payment, principal			$ 700
Hercules Term Loan [Member] \| Prime Rate [Member]
Percentage of loan bear interest rate		9.20%	12.50%
Riverside Merchant Partners, LLC [Member]
Debt principal amount			$ 3,000
Subordinated convertible promissory notes			3,000
Magna Note [Member]
Debt principal amount			763	$ 763
Magna Note [Member] \| Securities Purchase Agreement [Member]
Debt principal amount			$ 763		$ 3,500
Debt maturity date			Aug. 11, 2016
Percentage of loan bear interest rate			6.00%
First Amendment to Loan and Security Agreement [Member] \| Hercules Term Loan [Member]
Debt principal amount	$ 1,000		$ 7,000
Debt instrument, covenant description	The Amendment modified the liquidity covenant to reduce the minimum cash balance required by $500,000 for every $1.0 million paid in principal to a minimum of $2.5 million. The minimum cash and cash equivalents balance required to maintain compliance with the minimum liquidity covenant at March 31, 2016 was $7.0 million.
Debt principal balance	$ 2,500
First Amendment to Loan and Security Agreement [Member] \| Hercules Term Loan [Member] \| Minimum [Member]
Debt principal amount	$ 500
Hercules Technology Capital, Inc. [Member] \| Loan and Security Agreement [Member]
Debt principal amount		$ 20,000
Debt maturity date		Jan. 01, 2018
Hercules Term Loan [Member] \| Riverside Merchant Partners, LLC [Member]
Debt principal amount			$ 3,000

XML 48 R38.htm IDEA: XBRL DOCUMENT

Debt - Schedule of Outstanding Long-Term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Total debt, outstanding principal	$ 15,981	$ 17,814
Total debt, unamortized discount	(1,196)	(1,449)
Total debt, net carrying amount	14,785	16,365
Current portion, outstanding principal	(15,981)	(17,814)
Current portion, unamortized discount	(1,196)	1,449
Current portion, net carrying amount	$ (14,785)	$ (16,365)
Long-term debt, outstanding principal
Long-term debt, unamortized discount
Long-term debt
Hercules Term Loan [Member]
Debt Instrument [Line Items]
Total debt, outstanding principal	$ 15,218	$ 17,051
Total debt, unamortized discount	(1,186)	(1,420)
Total debt, net carrying amount	14,032	15,631
Magna Note [Member]
Debt Instrument [Line Items]
Total debt, outstanding principal	763	763
Total debt, unamortized discount	(10)	(29)
Total debt, net carrying amount	$ 753	$ 734

XML 49 R39.htm IDEA: XBRL DOCUMENT

Debt - Schedule of Future Principal Payments on Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Line of Credit Facility [Line Items]
Total future principal payments	$ 14,785	$ 16,365
Convertible Notes Payable [Member]
Line of Credit Facility [Line Items]
2016	6,550
2017	8,643
2018	788
Total future principal payments	15,981
Hercules Term Loan [Member]
Line of Credit Facility [Line Items]
Total future principal payments	14,032	15,631
Hercules Term Loan [Member] \| Convertible Notes Payable [Member]
Line of Credit Facility [Line Items]
2016	5,787
2017	8,643
2018	788
Total future principal payments	15,218
Magna Note [Member]
Line of Credit Facility [Line Items]
Total future principal payments	753	$ 734
Magna Note [Member] \| Convertible Notes Payable [Member]
Line of Credit Facility [Line Items]
2016	$ 763
2017
2018
Total future principal payments	$ 763

XML 50 R40.htm IDEA: XBRL DOCUMENT

Equity (Details Narrative) - Series A Warrants [Member] - shares	1 Months Ended
	Sep. 30, 2015	Mar. 31, 2016
Common stock shares, issued	536,388
Number of shares issued upon cashless exercise warrants	1,137,365
Outstanding warrants exercisable		100,000

XML 51 R41.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details Narrative) - 2012 Plan [Member] - shares	1 Months Ended
	Jan. 31, 2016	Mar. 31, 2016
Shares issuable with respect to awards granted	37,879
Shares issuable with respect to awards maximum shares	342,425
Number of shares available for grant		121,248

XML 52 R42.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2016 $ / shares shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options, Outstanding at beginning of period \| shares	112,373
Options, Granted \| shares	23,004
Options, Expired \| shares	13,702
Options, Outstanding at end of period \| shares	121,675
Options, Exercisable at end of period \| shares	74,859
Options, Vested and expected to vest at end of period \| shares	119,112
Weighted Average Exercise Price, Outstanding at beginning of period \| $ / shares	$ 41.53
Weighted Average Exercise Price, Granted \| $ / shares	1.69
Weighted Average Exercise Price, Expired \| $ / shares	24.17
Weighted Average Exercise Price, Outstanding at end of period \| $ / shares	35.95
Weighted Average Exercise Price, Exercisable at end of period \| $ / shares	60.65
Weighted Average Exercise Price, Vested and expected to vest at end of period \| $ / shares	$ 36.50

XML 53 R43.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Black-Scholes-Merton Option Pricing Model (Details) - Employee Stock Option [Member]	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average risk-free interest rate	1.86%	1.62%
Weighted-average expected life (in years)	6 years 3 months 18 days	6 years 3 months 18 days
Expected dividend yield	0.00%	0.00%
Weighted-average expected volatility	65.00%	46.00%

XML 54 R44.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 90	$ 660
Cost Of Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	4	29
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	29	122
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	40	328
Selling and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	15	142
Capitalized Into Inventory [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 2	$ 39

XML 55 R45.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Unrecognized Compensation Cost, Nonvested Awards (Details) - Employee Stock Option [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2016 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation	$ 435
Weighted average remaining period of recognition (in years)	1 year 8 months 12 days

XML 56 R46.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) $ in Thousands	Nov. 06, 2014 USD ($)
Commitments And Contingencies Details Narrative
Seeks damages amount	$ 1,000

XML 57 R47.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands						3 Months Ended
	May. 13, 2016	May. 06, 2016	Apr. 27, 2016	Apr. 18, 2016	Apr. 04, 2016	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Subsequent Event [Line Items]
Debt principal amount						$ 15,981		$ 17,814
Option to purchase of principal amount outstanding							$ 202
Subsequent Event [Member] \| Assignment Agreement [Member] \| Riverside Merchant Partners, LLC [Member]
Subsequent Event [Line Items]
Debt principal amount					$ 1,000
Option to purchase of principal amount outstanding					$ 2,000
Debt periodic principal amount			$ 1,000	$ 1,000
Subsequent Event [Member] \| Exchange Agreement [Member]
Subsequent Event [Line Items]
Debt conversion price per share					$ 1.34
Debt fixed conversion price per share					$ 1.43
Debt maturity date					Apr. 03, 2018
Percentage of debt bear interest rate					6.00%
Debt payment terms					12 months
Subsequent Event [Member] \| Exchange Agreement [Member] \| Riverside Merchant Partners, LLC [Member]
Subsequent Event [Line Items]
Debt principal amount				1,000	$ 1,000
Option to purchase of principal amount outstanding			1,000		2,000
Subordinated convertible promissory notes			$ 1,000	$ 1,000	$ 1,000
Warrants to purchase of shares of common stock			100,000		100,000
Debt conversion price per share			$ 1.66		$ 1.62
Subsequent Event [Member] \| Exchange Agreement [Member] \| Riverside Merchant Partners, LLC [Member] \| Hercules Term Loan [Member]
Subsequent Event [Line Items]
Subordinated convertible promissory notes					$ 2,000
Warrants to purchase of shares of common stock					100,000
Subsequent Event [Member] \| Third Exchange Note [Member] \| Riverside Merchant Partners, LLC [Member]
Subsequent Event [Line Items]
Debt principal amount	$ 800
Debt conversion into common stock shares		140,000
Subsequent Event [Member] \| First Exchange Note [Member] \| Riverside Merchant Partners, LLC [Member]
Subsequent Event [Line Items]
Option to purchase of principal amount outstanding	$ 200
Debt conversion into common stock shares	1,672,788

EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 110 186 1 false 41 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://amedica.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://amedica.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://amedica.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://amedica.com/role/StatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://amedica.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://amedica.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 6 false false R7.htm 00000007 - Disclosure - Basic and Diluted Net Loss Per Common Share Sheet http://amedica.com/role/BasicAndDilutedNetLossPerCommonShare Basic and Diluted Net Loss Per Common Share Notes 7 false false R8.htm 00000008 - Disclosure - Inventories Sheet http://amedica.com/role/Inventories Inventories Notes 8 false false R9.htm 00000009 - Disclosure - Intangible Assets Sheet http://amedica.com/role/IntangibleAssets Intangible Assets Notes 9 false false R10.htm 00000010 - Disclosure - Fair Value Measurements Sheet http://amedica.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 00000011 - Disclosure - Accrued Liabilities Sheet http://amedica.com/role/AccruedLiabilities Accrued Liabilities Notes 11 false false R12.htm 00000012 - Disclosure - Debt Sheet http://amedica.com/role/Debt Debt Notes 12 false false R13.htm 00000013 - Disclosure - Equity Sheet http://amedica.com/role/Equity Equity Notes 13 false false R14.htm 00000014 - Disclosure - Stock-Based Compensation Sheet http://amedica.com/role/Stock-basedCompensation Stock-Based Compensation Notes 14 false false R15.htm 00000015 - Disclosure - Commitments and Contingencies Sheet http://amedica.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Subsequent Events Sheet http://amedica.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://amedica.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://amedica.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) Sheet http://amedica.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables Organization and Summary of Significant Accounting Policies (Tables) Tables http://amedica.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Inventories (Tables) Sheet http://amedica.com/role/InventoriesTables Inventories (Tables) Tables http://amedica.com/role/Inventories 19 false false R20.htm 00000020 - Disclosure - Intangible Assets (Tables) Sheet http://amedica.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://amedica.com/role/IntangibleAssets 20 false false R21.htm 00000021 - Disclosure - Fair Value Measurements (Tables) Sheet http://amedica.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://amedica.com/role/FairValueMeasurements 21 false false R22.htm 00000022 - Disclosure - Accrued Liabilities (Tables) Sheet http://amedica.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://amedica.com/role/AccruedLiabilities 22 false false R23.htm 00000023 - Disclosure - Debt (Tables) Sheet http://amedica.com/role/DebtTables Debt (Tables) Tables http://amedica.com/role/Debt 23 false false R24.htm 00000024 - Disclosure - Stock-Based Compensation (Tables) Sheet http://amedica.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://amedica.com/role/Stock-basedCompensation 24 false false R25.htm 00000025 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) Sheet http://amedica.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Organization and Summary of Significant Accounting Policies (Details Narrative) Details http://amedica.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - Organization and Summary of Significant Accounting Policies - Schedule of Reconciliation of Effect of Reclassifications on Condensed Consolidated Balance Sheet (Details) Sheet http://amedica.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies-ScheduleOfReconciliationOfEffectOfReclassificationsOnCondensedConsolidatedBalanceSheetDetails Organization and Summary of Significant Accounting Policies - Schedule of Reconciliation of Effect of Reclassifications on Condensed Consolidated Balance Sheet (Details) Details 26 false false R27.htm 00000027 - Disclosure - Basic and Diluted Net Loss Per Common Share (Details Narrative) Sheet http://amedica.com/role/BasicAndDilutedNetLossPerCommonShareDetailsNarrative Basic and Diluted Net Loss Per Common Share (Details Narrative) Details http://amedica.com/role/BasicAndDilutedNetLossPerCommonShare 27 false false R28.htm 00000028 - Disclosure - Inventories (Details Narrative) Sheet http://amedica.com/role/InventoriesDetailsNarrative Inventories (Details Narrative) Details http://amedica.com/role/InventoriesTables 28 false false R29.htm 00000029 - Disclosure - Inventories - Components of Inventory (Details) Sheet http://amedica.com/role/Inventories-ComponentsOfInventoryDetails Inventories - Components of Inventory (Details) Details 29 false false R30.htm 00000030 - Disclosure - Intangible Assets (Details Narrative) Sheet http://amedica.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://amedica.com/role/IntangibleAssetsTables 30 false false R31.htm 00000031 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://amedica.com/role/IntangibleAssets-ScheduleOfIntangibleAssetsDetails Intangible Assets - Schedule of Intangible Assets (Details) Details 31 false false R32.htm 00000032 - Disclosure - Fair Value Measurements (Details Narrative) Sheet http://amedica.com/role/FairValueMeasurementsDetailsNarrative Fair Value Measurements (Details Narrative) Details http://amedica.com/role/FairValueMeasurementsTables 32 false false R33.htm 00000033 - Disclosure - Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Details) Sheet http://amedica.com/role/FairValueMeasurements-ScheduleOfFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Details) Details 33 false false R34.htm 00000034 - Disclosure - Fair Value Measurements - Schedule of Reconciliation of Derivative Liability Measured on Recurring Basis Using Unobservable Inputs (Level 3) (Details) Sheet http://amedica.com/role/FairValueMeasurements-ScheduleOfReconciliationOfDerivativeLiabilityMeasuredOnRecurringBasisUsingUnobservableInputsLevel3Details Fair Value Measurements - Schedule of Reconciliation of Derivative Liability Measured on Recurring Basis Using Unobservable Inputs (Level 3) (Details) Details 34 false false R35.htm 00000035 - Disclosure - Fair Value Measurements - Schedule of Assumptions used in Estimating Common Stock Warrant Liability (Details) Sheet http://amedica.com/role/FairValueMeasurements-ScheduleOfAssumptionsUsedInEstimatingCommonStockWarrantLiabilityDetails Fair Value Measurements - Schedule of Assumptions used in Estimating Common Stock Warrant Liability (Details) Details 35 false false R36.htm 00000036 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) Sheet http://amedica.com/role/AccruedLiabilities-ScheduleOfAccruedLiabilitiesDetails Accrued Liabilities - Schedule of Accrued Liabilities (Details) Details 36 false false R37.htm 00000037 - Disclosure - Debt (Details Narrative) Sheet http://amedica.com/role/DebtDetailsNarrative Debt (Details Narrative) Details http://amedica.com/role/DebtTables 37 false false R38.htm 00000038 - Disclosure - Debt - Schedule of Outstanding Long-Term Debt (Details) Sheet http://amedica.com/role/Debt-ScheduleOfOutstandingLong-termDebtDetails Debt - Schedule of Outstanding Long-Term Debt (Details) Details 38 false false R39.htm 00000039 - Disclosure - Debt - Schedule of Future Principal Payments on Debt (Details) Sheet http://amedica.com/role/Debt-ScheduleOfFuturePrincipalPaymentsOnDebtDetails Debt - Schedule of Future Principal Payments on Debt (Details) Details 39 false false R40.htm 00000040 - Disclosure - Equity (Details Narrative) Sheet http://amedica.com/role/EquityDetailsNarrative Equity (Details Narrative) Details http://amedica.com/role/Equity 40 false false R41.htm 00000041 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://amedica.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://amedica.com/role/Stock-basedCompensationTables 41 false false R42.htm 00000042 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) Sheet http://amedica.com/role/Stock-basedCompensation-SummaryOfStockOptionActivityDetails Stock-Based Compensation - Summary of Stock Option Activity (Details) Details 42 false false R43.htm 00000043 - Disclosure - Stock-Based Compensation - Schedule of Black-Scholes-Merton Option Pricing Model (Details) Sheet http://amedica.com/role/Stock-basedCompensation-ScheduleOfBlack-scholes-mertonOptionPricingModelDetails Stock-Based Compensation - Schedule of Black-Scholes-Merton Option Pricing Model (Details) Details 43 false false R44.htm 00000044 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) Sheet http://amedica.com/role/Stock-basedCompensation-ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails Stock-Based Compensation - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) Details 44 false false R45.htm 00000045 - Disclosure - Stock-Based Compensation - Schedule of Unrecognized Compensation Cost, Nonvested Awards (Details) Sheet http://amedica.com/role/Stock-basedCompensation-ScheduleOfUnrecognizedCompensationCostNonvestedAwardsDetails Stock-Based Compensation - Schedule of Unrecognized Compensation Cost, Nonvested Awards (Details) Details 45 false false R46.htm 00000046 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://amedica.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://amedica.com/role/CommitmentsAndContingencies 46 false false R47.htm 00000047 - Disclosure - Subsequent Events (Details Narrative) Sheet http://amedica.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://amedica.com/role/SubsequentEvents 47 false false All Reports Book All Reports amda-20160331.xml amda-20160331.xsd amda-20160331_cal.xml amda-20160331_def.xml amda-20160331_lab.xml amda-20160331_pre.xml true true ZIP 64 0001493152-16-009773-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-16-009773-xbrl.zip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~~&UL4$L%!@ & 8 B@$ *-% 0 $! end~~